[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4635
1. Zhong BY, Fan XG, Liu WD, Yang YX, You YH: [Establishment of 2-dimensional electrophoresis maps of peripheral blood mononuclear cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr;32(2):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To establish the 2-dimensional electrophoresis(2-DE) profiles of peripheral blood mononuclear cells(PBMC) in patients with hepatocellular carcinoma(HCC) and health adults.
  • METHODS: The total proteins from PBMC in patients with HCC and healthy adult were separated by immobilized pH gradient-based 2-DE.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / blood. Female. Humans. Liver Neoplasms / blood. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478940.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Oyunsuren T, Sanduijav R, Davaadorj D, Nansalmaa D: Hepatocellular carcinoma and its early detection by AFP testing in Mongolia. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):460-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma and its early detection by AFP testing in Mongolia.
  • Liver cancer is one of the leading causes of cancer death in Mongolia.
  • In the period 2000-2005 years 35.3%of all newly registered cancer cases were liver cancers, with an incidence rate of 51.3 per 100,000 population.
  • Sera from a total of 513 patients with chronic liver diseases, liver cirrhosis and HCC were analyzed for liver function (ALAT, ASAT) and hepatitis virus markers (HBsAg, anti-HCV).
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Liver Cirrhosis / diagnosis. Liver Neoplasms / diagnosis. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Early Diagnosis. Female. Hepacivirus / isolation & purification. Hepatitis B / blood. Hepatitis B / complications. Hepatitis B Surface Antigens / blood. Hepatitis B virus / isolation & purification. Hepatitis C / blood. Hepatitis C / complications. Humans. Incidence. Male. Middle Aged. Mongolia / epidemiology

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059345.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hepatitis B Surface Antigens; 0 / alpha-Fetoproteins
  •  go-up   go-down


3. Crum NF: Epstein Barr virus hepatitis: case series and review. South Med J; 2006 May;99(5):544-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein Barr virus (EBV) infection causes asymptomatic liver-associated enzyme abnormalities in 80 to 90% of cases which are often unrecognized.
  • Other gastrointestinal complications associated with EBV may include splenic rupture, liver failure due to acute and/or chronic EBV infection, and perhaps, autoimmune hepatitis and hepatocellular carcinoma.
  • [MeSH-minor] Adolescent. Adult. Humans. Male


Advertisement
4. Malik SM, Gupte PA, de Vera ME, Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol; 2009 Jul;7(7):800-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
  • BACKGROUND & AIMS: The increasing incidence of hepatocellular carcinoma in the United States is only partially accounted for by hepatitis C virus (HCV) infections.
  • The prevalence of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (NASH) is not known; guidelines from the American Association for the Study of Liver Diseases do not recommend surveillance imaging.
  • We sought to determine the prevalence of hepatocellular carcinoma among patients undergoing liver transplantation for NASH-related cirrhosis and their outcome after surgery, compared with controls.
  • METHODS: We reviewed the records of adult patients with NASH cirrhosis who underwent liver transplantation by using a prospectively collected database from a single center.
  • Data from patients with NASH cirrhosis were compared with matched controls who received transplantation for primary biliary cirrhosis/primary sclerosing cholangitis, alcoholic liver disease, or HCV.
  • RESULTS: Seventeen of 98 patients (17%) with NASH cirrhosis were diagnosed with hepatocellular carcinoma.
  • Six patients were diagnosed with hepatocellular carcinoma incidentally on explant.
  • Survival after liver transplantation was 88% after mean follow-up of 2.5 years.
  • The number of NASH patients known to have hepatocellular carcinoma before liver transplantation was greater than the number of patients with primary biliary cirrhosis/primary sclerosing cholangitis and comparable to the number of patients with alcoholic liver disease and HCV.
  • CONCLUSIONS: Patients with NASH cirrhosis are at risk for developing hepatocellular carcinoma; patients with NASH cirrhosis, especially men older than 50 years, should undergo surveillance imaging.
  • Patients with NASH and hepatocellular carcinoma have good outcomes after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / surgery. Fatty Liver / complications. Fatty Liver / epidemiology. Liver Transplantation
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2009 Oct;15(10):1367-8 [19806686.001]
  • (PMID = 19281869.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J, GESIDA3603/5607 Study Group: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology; 2009 Aug;50(2):407-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
  • Human immunodeficiency virus (HIV) infection modifies the natural history of chronic hepatitis C, thus promoting more rapid progression to cirrhosis and end-stage liver disease.
  • We measured sustained virologic response (SVR), i.e., undetectable HCV RNA at 24 weeks after the end of treatment, and clinical outcomes, defined as death (liver-related or non-liver-related), liver decompensation, hepatocellular carcinoma, and liver transplantation.
  • During a mean follow-up of 20.8 months (interquartile range: 12.2-38.7), the incidence rates per 100 person-years of overall mortality, liver-related mortality, and liver decompensation were 0.46, 0.23, and 0.23 among patients with SVR and 3.12, 1.65, and 4.33 among those without SVR (P = 0.003, 0.028, and <0.001 by the log-rank test), respectively.
  • Cox regression analysis adjusted for fibrosis, HCV genotype, HCV RNA viral load, Centers for Disease Control and Prevention clinical category, and nadir CD4+ cell count showed that the adjusted hazard ratio of liver-related events was 8.92 (95% confidence interval, 1.20; 66.11, P = 0.032) for nonresponders in comparison with responders and 4.96 (95% confidence interval, 2.27; 10.85, P < 0.001) for patients with fibrosis grade of F3-F4 versus those with F0-F2.Because this was not a prospective study, selection and survival biases may influence estimates of effect.
  • CONCLUSION: Our results suggest that the achievement of an SVR after interferon-ribavirin therapy in patients coinfected with HIV/HCV reduces liver-related complications and mortality.
  • [MeSH-minor] Adult. Cohort Studies. Drug Therapy, Combination. Female. Humans. Male. Treatment Outcome


6. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology; 2008;75 Suppl 1:83-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.
  • OBJECTIVES: The conventional Japan Integrated Staging (c-JIS) score has been reported to effectively stratify patients with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Japan. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19092276.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Bian DJ, Xiao EH, Hu DX, Chen XY, Situ WJ, Yuan SW, Sun JL, Yang LP: Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J Cancer; 2010 Feb;29(2):198-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization.
  • BACKGROUND AND OBJECTIVE: Proton magnetic resonance spectroscopy (MRS) of the liver in vivo is in experimental phase.
  • MRS observation on liver cancer after transcatheter arterial chemoembolization (TACE) has seldom been reported.
  • This study was to investigate the value of MRS in assessing the metabolic changes of hepatocellular carcinoma (HCC) after TACE.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Aged. Choline / metabolism. Female. Glucose / metabolism. Glutamic Acid / metabolism. Glutamine / metabolism. Glycogen / metabolism. Humans. Lipids / analysis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20109351.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids; 0RH81L854J / Glutamine; 3KX376GY7L / Glutamic Acid; 9005-79-2 / Glycogen; IY9XDZ35W2 / Glucose; N91BDP6H0X / Choline
  •  go-up   go-down


8. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M: Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol; 2006 Mar;37(3):283-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
  • Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components.
  • The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent.
  • The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% +/- 12.9%, 25.4% +/- 18.3%, and 46.0% +/- 23.6%, respectively.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / secondary. Cholangiocarcinoma / secondary. Liver Neoplasms / pathology. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasms, Multiple Primary. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613323.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Sotiropoulos GC, Lang H, Sgourakis G, Nadalin S, Molmenti EP, Radtke A, Paul A, Beckebaum S, Saner FH, Baba HA, Gerken G, Malagó M, Broelsch CE: Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned. Dig Dis Sci; 2009 Feb;54(2):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned.
  • BACKGROUND: Living donor liver transplantation (LDLT) in cases of hepatocellular carcinoma (HCC) that do not fulfil accepted tumor criteria continues to be a matter of controversy.
  • In contrast, the Model for End stage Liver Disease (MELD) score predicted survival only when 45-day mortality was included in the analysis, while alpha fetoprotein (AFP) level predicted survival only when it was excluded.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / mortality. Living Donors. Patient Selection
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Female. Germany / epidemiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Proportional Hazards Models. Young Adult


10. Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, Sasaki Y: Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol; 2010;45(1):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma.
  • PURPOSE: The aim of this study was to investigate the antitumor efficacy of treatment, identify prognostic factors, and construct a prognostic index in patients with hepatocellular carcinoma treated by transcatheter arterial infusion chemotherapy (TAI) using cisplatin suspended in lipiodol.
  • METHODS: We analyzed the outcomes in a total of 94 consecutive patients with previously untreated hepatocellular carcinoma who were treated by TAI using cisplatin suspended in lipiodol.
  • CONCLUSIONS: TAI with cisplatin suspended in lipiodol exhibited favorable tumor efficacy and survival in patients with hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Iodized Oil / chemistry. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):50-7 [10618605.001]
  • [Cites] Radiology. 1987 May;163(2):345-51 [3031724.001]
  • [Cites] Jpn J Clin Oncol. 2002 Nov;32(11):455-60 [12499417.001]
  • [Cites] J Gastroenterol. 2008;43(2):159-70 [18306990.001]
  • [Cites] J Hepatol. 1990 Sep;11(2):181-4 [2174933.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] Oncology. 2002;62(3):228-33 [12065870.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S149-52 [8137478.001]
  • [Cites] Hepatol Res. 2008 May;38(5):474-83 [18430093.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):169-76 [14739665.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] J Gastroenterol. 2008;43(5):369-77 [18592155.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Cardiovasc Intervent Radiol. 1993 Jul-Aug;16(4):209-13 [8402781.001]
  • [Cites] Oncology. 2000 May;58(4):293-9 [10838494.001]
  • [Cites] J Gastroenterol. 2005 Jan;40(1):70-8 [15692792.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):453-6 [2826285.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] J Gastroenterol. 2007 Oct;42(10 ):845-53 [17940838.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Oncology. 2004;66(1):24-31 [15031595.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):439-52 [15166617.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1586-94 [2477131.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7561-7 [17171782.001]
  • (PMID = 19655081.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8001-40-9 / Iodized Oil; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T: Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol; 2008 Jul;6(7):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
  • BACKGROUND & AIMS: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer.
  • METHODS: We prospectively studied 1131 consecutive patients without a history of liver disease seen for diabetes.
  • The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy.
  • A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma.
  • In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696).
  • [MeSH-major] Diabetes Complications. Liver Cirrhosis / epidemiology. Liver Function Tests / methods. Mass Screening / methods
  • [MeSH-minor] Adult. Aged. Biomarkers. Biopsy. Elasticity Imaging Techniques. Endoscopy. Female. Humans. Liver / pathology. Male. Middle Aged. Prevalence. Prospective Studies. Severity of Illness Index. Ultrasonography

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524692.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


12. Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, Shiraha H, Koide N: Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology; 2008;51(1):59-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.
  • AIMS: To prospectively study whether occult hepatitis B virus (HBV) infection can promote the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related chronic liver disease.
  • METHODS: A total of 167 patients with HCV-related chronic liver disease without HBV surface antigen (HBsAg) were studied.
  • HBV DNA in liver tissue was determined using polymerase chain reaction (PCR).
  • CONCLUSION: A high amount of HBV DNA in liver tissue of HBsAg-negative patients with HCV-related liver disease might be associated with HCC development.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. DNA, Viral / isolation & purification. Hepatitis B / virology. Hepatitis B virus / isolation & purification. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / virology. Liver / virology
  • [MeSH-minor] Adult. Aged. Female. Hepatitis B Surface Antigens / blood. Humans. Incidence. Liver Diseases. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 S. Karger AG, Basel.
  • (PMID = 18349544.001).
  • [ISSN] 1423-0100
  • [Journal-full-title] Intervirology
  • [ISO-abbreviation] Intervirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


13. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ozdil B: Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol; 2010 Jun;34(3):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study.
  • We examined the association between this CCDN1 genotype and the susceptibility to hepatocellular carcinoma (HCC) in a Turkish population.
  • Hospital-based case-control study was designed consisting of 160 diagnosis subjects with hepatocellular carcinoma and 160 cancer-free control subjects matched on age, gender, smoking and alcohol status.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Cyclin D1 / genetics. Liver Neoplasms / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Population. Population Surveillance. Risk Factors. Turkey / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20347627.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  •  go-up   go-down


14. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM: Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood); 2009 Jun;234(6):693-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences.
  • Hepatocellular carcinoma (HCC) commonly develops in patients with underlying chronic liver disease.
  • Additionally, the tumorous lesions of HCC patients are consistently characterized by the lack of iron accumulation even when arising in iron-loaded liver.
  • In this study, all tumorous tissues from 24 HCC patients with chronic HBV infection were stained negative for iron when histologically assessed by Perls' Prussian blue stain, whereas excess iron deposits were present in 17 of the 24 adjacent non-tumorous liver tissues.
  • To elucidate the concerted regulation of iron homeostasis in these patients, we studied the gene expression profiling of 42 relevant iron-regulatory genes in the tumorous and adjacent non-tumorous liver tissues of these HCC patients along with 10 normal liver controls.
  • Expression for most of the iron-regulatory genes, including hepcidin, transferrin receptor 2 (TfR2), transferrin (Tf), ceruloplasmin (Cp) and iron regulatory protein 1 (IRP1), were significantly down-regulated in the tumorous tissues of these patients compared to the adjacent non-tumorous liver tissues and normal liver controls.
  • On the other hand, expression of hepcidin, TfR2, ferroportin 1 and DMT1 were significantly up-regulated in iron-loaded non-cirrhotic non-tumorous liver tissues as compared with normal liver controls.
  • Hence, the reduction of hepcidin expression within the iron-depleted tumorous lesions likely reflects the physiological consequence of the obligate demand for iron in the rapidly growing neoplastic cells, whereas the up-regulation of hepcidin expression in the iron-loaded adjacent non-tumorous liver tissues is likely a physiological response.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Gene Expression Regulation, Neoplastic. Hepatitis B, Chronic / metabolism. Hepatitis C, Chronic / metabolism. Iron / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307463.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; E1UOL152H7 / Iron
  •  go-up   go-down


15. Chekmareva IA, Vtiurin BV, Dubova EA, Shchegolev AI: [Ultrastructural characteristics of hepatocellular carcinoma]. Arkh Patol; 2010 May-Jun;72(3):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrastructural characteristics of hepatocellular carcinoma].
  • The histological study diagnosed low-, moderate, and high-grade hepatocellular carcinoma in 5, 12, 5 patients, respectively.
  • The high-grade type was characterized by the signs of significant cell structural and functional rearrangement; changes in the number, sizes, and shape of intracellular masses (a nucleus, mitochondria, endoplasmic network, lysosomes).
  • [MeSH-major] Carcinoma, Hepatocellular / ultrastructure. Liver Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Female. Humans. Liver / ultrastructure. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734825.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


16. Zhu C, Zhang R, Liu L, Rasool ST, Mu Y, Sun W, Hao Q, Liu F, Zhu Y, Wu J: Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin Immunol; 2009 Apr;131(1):92-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-27 was also detected at higher levels in patients with liver cirrhosis or hepatocellular carcinoma than those with acute hepatitis B or chronic hepatitis B (P<0.05).
  • [MeSH-minor] Acute Disease. Adult. Antigen Presentation. Cell Line. Female. Hepatitis B Surface Antigens / blood. Hepatitis B Surface Antigens / immunology. Hepatitis B e Antigens / blood. Hepatitis B e Antigens / immunology. Hepatitis B, Chronic / blood. Hepatitis B, Chronic / immunology. Hepatitis B, Chronic / virology. Humans. Male. Middle Aged. Monocytes. Transfection. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081304.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C19orf10 protein, human; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens; 0 / IL27 protein, human; 0 / Interleukins
  •  go-up   go-down


17. Wang H, Zhang J, Feng W, Zhang S, Liang H, Wang Y, Zheng Q, Li Z: PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance. J Huazhong Univ Sci Technolog Med Sci; 2007 Feb;27(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance.
  • The evolution of hepatocellular carcinoma (HCC) is a compound process which involves many kinds of genes and transductional pathways.
  • The expression of the peptidyl-proplyl-isomerase PIN1 gene, the mutation in exon 3 of beta-catenin and its correspondent abnormal expression and their roles in the hepatocellular carcinogeneisis were investigated.
  • Among 29 pair cases of HCC and non-carcinoma tissues, the expression of PIN1 gene was detected by immunochemical staining.
  • (3) 24.1% (7/29) of primary tumor lesions carried gene mutations in exon 3 of beta-catenin, and accompanied by beta-catenin protein accumulation.
  • So it was postulated that the increase of PIN1 gene expression could promote hepatocellular carcinogenesis via a way different from beta-catenin gene mutation.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Mutation. Peptidylprolyl Isomerase / genetics. beta Catenin / genetics
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Cytoplasm / metabolism. DNA, Neoplasm / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. NIMA-Interacting Peptidylprolyl Isomerase. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):264-7 [12515622.001]
  • [Cites] Pathology. 2004 Apr;36(2):120-8 [15203747.001]
  • [Cites] Chin Med J (Engl). 2006 Jul 5;119(13):1113-7 [16834931.001]
  • [Cites] Oncogene. 2004 May 20;23 (23 ):4182-6 [15064734.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Mar;18(3):280-7 [12603528.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31 [15300008.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3145-53 [12810642.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):793-801 [11533658.001]
  • [Cites] J Cell Sci. 2003 Mar 1;116(Pt 5):773-83 [12571275.001]
  • [Cites] Am J Clin Pathol. 2004 Sep;122(3):377-82 [15362367.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):435-42 [12663502.001]
  • (PMID = 17393110.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / NIMA-Interacting Peptidylprolyl Isomerase; 0 / beta Catenin; EC 5.2.1.8 / PIN1 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


18. Fazi C, Dagklis A, Cottini F, Scarfò L, Bertilaccio MT, Finazzi R, Memoli M, Ghia P: Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry B Clin Cytom; 2010;78 Suppl 1:S61-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.
  • BACKGROUND: Monoclonal B cell lymphocytosis (MBL) is a preclinical condition characterized by an expansion of clonal B cells in the absence of B lymphocytosis (BALC < 5 × 10(9)/L) in the peripheral blood, without clinical signs, suggestive of a lymphoproliferative disorder.
  • B cell clonal expansions are also associated with hepatitis C virus (HCV) infection and they can evolve into lymphoproliferative disorders such as mixed cryoglobulinemia and non-Hodgkin lymphomas (NHL).
  • METHODS: By five-colour flow cytometry, we analyzed 123 HCV positive subjects with diagnosis of chronic hepatitis (94) or cirrhosis (29); 16 of those with cirrhosis had a diagnosis of hepatocellular carcinoma.
  • Twenty-four/ninety-four (25.5%) patients affected by chronic hepatitis had MBL, whereas 11/29 (37.9%) patients with cirrhosis showed a B cell clone.
  • The persistence of HCV may be responsible for the dysregulation of the immune system and in particular of the B cell compartment.
  • [MeSH-major] B-Lymphocytes / pathology. Hepatitis C, Chronic / pathology. Leukocytosis / pathology. Liver Cirrhosis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / pathology. Clone Cells. Female. Flow Cytometry. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Hepacivirus / genetics. Hepacivirus / immunology. Hepacivirus / isolation & purification. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Liver Neoplasms / etiology. Liver Neoplasms / pathology. Lymphocyte Count. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Clinical Cytometry Society.
  • (PMID = 20839339.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


19. He F, Yan Q, Fan L, Liu Y, Cui J, Wang J, Wang L, Wang Y, Wang Z, Guo Y, Huang G: PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum Pathol; 2010 Mar;41(3):415-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
  • The increased expression of PDZ binding kinase/lymphokine-activated killer T-cell-originated protein kinase (PBK/TOPK) is associated with some human malignant tumors.
  • In this study, we analyzed PBK/TOPK expression in hepatic primary tumor and explored its role in cholangiocarcinoma biology.
  • Seventy-four cholangiocarcinomas, 33 hepatocellular carcinomas, and 10 normal liver tissues were prepared from paraffin-embedded specimens.
  • The protein, mRNA of PBK/TOPK, and cell cycle of cholangiocarcinoma cell line after PBK/TOPK suppression with small interfere RNA were studied by Western blot, semiquantitative reverse transcriptase-polymerase chain reaction, and flow cytometry, respectively.
  • PBK/TOPK was usually expressed in normal bile duct epithelial cells and much more frequently expressed in cholangiocarcinoma (68/74) but never expressed in hepatocytes and hepatocellular carcinomas (0/33).
  • PBK/TOPK protein could serve as a useful indicator for histopathologic differentiation between cholangiocarcinoma and hepatocellular carcinomas and the low expression of PBK/TOPK is predicative of poor survival in cholangiocarcinoma patients.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Bile Ducts / metabolism. Blotting, Western. Cell Cycle / physiology. Cell Line, Tumor. Cells, Cultured. Diagnosis, Differential. Epithelial Cells / metabolism. Female. Flow Cytometry. Gene Silencing. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Mitogen-Activated Protein Kinase Kinases. Prognosis. Proportional Hazards Models. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sex Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19954816.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 2.7.12.2 / PDZ-binding kinase
  •  go-up   go-down


20. Reichman TW, Bahramipour P, Barone A, Koneru B, Fisher A, Contractor D, Wilson D, Dela Torre A, Cho KC, Samanta A, Harrison LE: Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg; 2005 May-Jun;9(5):638-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) represents one of the most prevalent cancers worldwide.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic / methods. Liver Neoplasms / mortality. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis, Viral, Human / pathology. Hepatitis, Viral, Human / physiopathology. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2003 May;98(5):1181-5 [12809846.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):50-7 [10618605.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):753-8 [14585409.001]
  • [Cites] Radiology. 1987 May;163(2):345-51 [3031724.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5093-107 [12910247.001]
  • [Cites] Gut. 1993 Nov;34(11):1598-600 [8244149.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):759-64 [14585410.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S72-8 [15508106.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S130-7 [12449982.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):325-31 [12594668.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1501-8 [9118030.001]
  • [Cites] Am J Med. 1985 Mar;78(3):399-406 [2579551.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7314-8 [2847868.001]
  • [Cites] J Clin Gastroenterol. 1999 Jun;28(4):334-40 [10372931.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):453-6 [2826285.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S1-6 [1281041.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):109-14 [10694648.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2449-53 [7922999.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5493-500 [14654528.001]
  • (PMID = 15862257.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


21. Zhu YZ, Zhu R, Shi LG, Mao Y, Zheng GJ, Chen Q, Zhu HG: Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. Exp Mol Pathol; 2010 Dec;89(3):268-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver cell lines were stably transfected with HBx-expressing vector.
  • Some cases of HCC and corresponding noncancerous liver tissues were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. DNA (Cytosine-5-)-Methyltransferase / biosynthesis. Gene Expression Regulation, Neoplastic. Genes, p16. Liver Neoplasms / virology. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. DNA Methylation / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620135.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trans-Activators; 0 / hepatitis B virus X protein; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3A
  •  go-up   go-down


22. Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J, Tang JW, Chan AT, Chan PK: Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology; 2007 Jun;45(6):1382-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / mortality. Hepatitis B, Chronic / mortality. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Viral Load
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antiviral Agents / pharmacology. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / pharmacology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Recombinant Proteins. Survival Analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2007 Nov;46(5):1665-6; author reply 1666 [17969038.001]
  • (PMID = 17539025.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Irie T: New embolization microcoil consisting of firm and flexible segments: preliminary clinical experience. Cardiovasc Intervent Radiol; 2006 Nov-Dec;29(6):986-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Angiography, Digital Subtraction. Angiomyolipoma / therapy. Arteries / surgery. Blood Vessel Prosthesis / adverse effects. Carcinoma, Hepatocellular / therapy. Catheterization / instrumentation. Device Removal. Equipment Design. Feasibility Studies. Female. Follow-Up Studies. Foreign-Body Migration / etiology. Foreign-Body Migration / radiography. Graft Occlusion, Vascular / etiology. Graft Occlusion, Vascular / radiography. Histiocytoma, Malignant Fibrous / therapy. Humans. Infusions, Intra-Arterial / instrumentation. Liver Neoplasms / therapy. Male. Middle Aged. Peptic Ulcer Hemorrhage / etiology. Peptic Ulcer Hemorrhage / therapy. Platinum Compounds. Research Design. Stomach Ulcer / complications. Stomach Ulcer / therapy. Tomography, X-Ray Computed. Treatment Outcome. Urinary Bladder Neoplasms / therapy. Vascular Fistula / therapy. Vascular Neoplasms / therapy

  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967218.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds
  •  go-up   go-down


24. Wu JY, Yang W, Cui M, Yin SS, Gao W, Wu W, Yan K, Chen MH: Efficacy and feasibility of radiofrequency ablation for decompensated cirrhotic patients with hepatocellular carcinoma. Chin Med J (Engl); 2010 Aug 5;123(15):1967-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of radiofrequency ablation for decompensated cirrhotic patients with hepatocellular carcinoma.
  • BACKGROUND: Most HCC patients with decompensation of liver function lost the chance of surgical and/or interventional treatment.
  • The aim of this study was to evaluate feasibility and outcome of radiofrequency ablation (RFA) in treating hepatocellular carcinoma (HCC) patients with poor liver function (Child-Pugh class C), who are not suitable for surgery or hepatic artery chemo-embolization.
  • METHODS: Thirteen HCC patients (the number of tumors was 17) with liver function of Child-Pugh C (scores: 10.2 +/- 0.4) were included in the study.
  • One week after RFA, the liver enzymes elevated in 9 patients (69.2%), in 7 of them, the liver enzyme returned to pre-RFA level in 1 - 3 months.
  • The incidence of RFA-related complications was 13.6% (3/22 sessions), including 1 case of GI hemorrhage and 1 sub-capsular hemorrhage of the liver.
  • One patient with HCC over 5 cm who had fever and liver abscess after RFA, and was dead 2 months later due to liver function failure.
  • CONCLUSIONS: Minimal invasive RFA provides possible treatment modality for HCC patients with poor liver function, who are not candidates for surgical and/or interventional therapy.
  • For large HCC, due to the required extended treatment region, special attention should be paid to the possibility of acute liver failure.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation / methods. Liver Cirrhosis / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819526.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Lee KK, Kim DG, Moon IS, Lee MD, Park JH: Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol; 2010 Jan 1;101(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.
  • PURPOSE: Liver resection (LR) and liver transplantation (LT) are considered the only two potentially curative treatments for hepatocellular carcinoma (HCC).
  • HCC recurred more frequently after resection (51.5%) than it did after transplantation (29.5%) (P < 0.001), and HCC recurrence developed in the liver more frequently after LR than it did after LT (P = 0.002).
  • CONCLUSION: LT should be considered as the primary treatment in patients with HCC within the Milan criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


26. Chang CW, Wang TE, Chen LT, Chang WH, Leu YS, Fan YK, Chan YJ: Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. Med Oncol; 2008;25(3):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature.
  • Hepatocellular carcinoma with sinonasal metastasis is extremely rare.
  • We report a case of a 49-year-old man who had a history of synchronous hepatocellular carcinoma and verrucous carcinoma of tongue.
  • A painless and non-bleeding mass was found in the left nasal septum 16 months after hepatocellular carcinoma was diagnosed.
  • It was resected and proved to be metastatic hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Nasal Septum. Nose Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Carcinoma, Verrucous / surgery. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Sep 1;60(5):1107-10 [3038298.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Arch Otolaryngol. 1984 Jul;110(7):437-40 [6732584.001]
  • [Cites] Hepatol Res. 2005 Jul;32(3):163-72 [16024288.001]
  • [Cites] Laryngoscope. 1963 Jul;73:942-53 [14043146.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Cutis. 2000 Feb;65(2):107-9 [10696564.001]
  • [Cites] Arch Otolaryngol. 1984 Sep;110(9):624-7 [6089722.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):369-74 [7686441.001]
  • [Cites] J Formos Med Assoc. 2002 Oct;101(10):715-8 [12517047.001]
  • [Cites] Head Neck Surg. 1982 Sep-Oct;5(1):29-38 [6757187.001]
  • [Cites] Laryngoscope. 1966 Apr;76(4):621-50 [5930356.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] J Laryngol Otol. 1994 Jun;108(6):503-4 [8027653.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1547-50 [15162522.001]
  • [Cites] Indian J Gastroenterol. 1998 Jul-Sep;17 (3):111-2 [9695400.001]
  • [Cites] Korean J Hepatol. 2004 Sep;10(3):228-32 [15385718.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):863-77 [6295617.001]
  • [Cites] HNO. 1991 Jul;39(7):263-5 [1657838.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1171-3 [8289013.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Apr;263(4):305-7 [16177918.001]
  • [Cites] J Clin Gastroenterol. 1991 Apr;13(2):217-9 [1851774.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):932-3 [10828817.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Dig Surg. 2001;18(4):294-7 [11528139.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1343-53 [7882285.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Am J Otolaryngol. 2007 Jul-Aug;28(4):238-41 [17606038.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Mar;55(3):297-306 [9054922.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Aug;102(8):1055-61 [16124714.001]
  • [Cites] Cancer. 1993 May 15;71(10):2941-5 [7683965.001]
  • [Cites] Liver. 2000 Jun;20(3):228-33 [10902973.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Feb;32(1):97-100 [12653243.001]
  • (PMID = 18040899.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  • [Number-of-references] 36
  •  go-up   go-down


27. Chan SC, Fan ST, Lo CM, Liu CL, Wei WI, Chik BH, Wong J: A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg; 2008 Sep;248(3):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes.
  • OBJECTIVE: We analyzed a single center's experience over a decade of right liver living donor liver transplantation (RLDLT).
  • Their midterm outcomes were compared with patients receiving deceased donor liver transplantation (DDLT) of the same period in the same center.
  • The 5-year survival rate of recipients with hepatocellular carcinoma (HCC) (n = 65) was 65.7%.
  • [MeSH-major] Liver Diseases / surgery. Liver Transplantation / mortality. Living Donors
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / surgery. Female. Hepatectomy. Humans. Liver Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome


28. Hashimoto K, Sasaki Y, Yokoyama S, Hiraki M, Matsumoto S, Tokuoka M, Matsuyama J, Morita S, Morimoto T, Fukushima Y, Nomura T, Takeda M: [Three-time resection of the rib metastasis from hepatocellular carcinoma after two hepatic resections--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2664-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-time resection of the rib metastasis from hepatocellular carcinoma after two hepatic resections--a case report].
  • A 40s woman, who had undergone hepatic resection twice for hepatocellular carcinoma (HCC), was admitted to our hospital because of a tumor with pain on the right 9th rib.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Ribs
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Recurrence, Local. Reoperation

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224673.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Petrolla AA, Xin W: Hepatic angiomyolipoma. Arch Pathol Lab Med; 2008 Oct;132(10):1679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic angiomyolipoma is a rare, benign, hepatic mesenchymal neoplasm found in both males and females, and most commonly in adult females.
  • The liver represents the second most frequent site of involvement.
  • The smooth muscle cell component is the most specific to the diagnosis.
  • The differential diagnosis includes hepatocellular carcinoma, hepatic adenoma, leiomyoma, hepatoblastoma, melanoma, and gastrointestinal stromal tumor.
  • The immunohistochemical staining pattern differentiates this lesion from other malignant and benign liver lesions.
  • [MeSH-major] Angiomyolipoma / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hepatic angiomyolipoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834230.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  • [Number-of-references] 17
  •  go-up   go-down


30. Hishinuma M, Ohashi KI, Yamauchi N, Kashima T, Uozaki H, Ota S, Kodama T, Aburatani H, Fukayama M: Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology; 2006 Nov;49(5):479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma.
  • AIMS: Glypican 3 (GPC3) is a cell surface heparan sulphate proteoglycan expressed specifically in the fetal liver and malignant neoplasms of hepatocyte lineage.
  • The aim was to evaluate the significance of GPC3 in alpha-fetoprotein (AFP)-producing gastric carcinoma (GC) and other forms of GC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064293.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / alpha-Fetoproteins
  •  go-up   go-down


31. Jang BK, Lee SH, Chung WJ, Park KS, Cho KB, Hwang JS, Kim YH, Choi JS, Kwon JH: [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma]. Korean J Hepatol; 2008 Jun;14(2):168-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
  • BACKGROUND/AIMS: Transcatheter arterial chemoembolization (TACE) is a major modality in the treatment of unresectable hepatocellular carcinoma.
  • Acute renal failure (ARF) may occur after TACE because of underlying liver cirrhosis and the presence of radiocontrast agent.
  • Univariate analysis revealed that serum albumin levels (P=0.025), Model for End-Stage Liver Disease score (P=0.001), the distribution of Child-Pugh class (P=0.027), and the proportions of patients with ascites (P<0.001), using diuretics (P=0.010), and with a serum creatinine level > or = 1.5 mg/dL (P=0.023) differed significantly between patients with or without ARF after TACE.
  • [MeSH-major] Acute Kidney Injury / epidemiology. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / adverse effects. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Creatinine / blood. Female. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617764.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


32. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K: Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg; 2005 Nov;201(5):663-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival.
  • BACKGROUND: The aim of this study was to identify factors predictive of survival after curative resection of hepatocellular carcinoma (HCC) in noncirrhotic liver.
  • STUDY DESIGN: Eighty-four patients underwent resection of HCC in noncirrhotic liver between January 1998 and December 2003.
  • Univariate and multivariable analyses were used to retrospectively identify factors associated with overall survival and disease-free survival when resection was curative for the primary tumor.
  • RESULTS: Overall 1-, 3-, and 5-year survival rates were 77.8%, 55.0%, and 44.4%, respectively, and 84.0%, 62.0%, and 50.0% when resection was curative for the primary tumor.
  • CONCLUSIONS: Aggressive operation is an effective treatment for HCC in noncirrhotic patients, whatever the degree of liver fibrosis.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256907.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gulati G, Saran RK: Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma: recognizing the oncocytic hepatocyte. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):288-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma: recognizing the oncocytic hepatocyte.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Hepatocytes / pathology. Liver / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Female. Humans

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332950.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


34. Zhao M, Wu PH, Zeng YX, Zhang FJ, Huang JH, Fan WJ, Gu YK, Zhang L, Tan ZB, Lin YE: [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Ai Zheng; 2005 Sep;24(9):1118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT].
  • BACKGROUND & OBJECTIVE: Judging tumor residue of hepatocellular carcinoma (HCC) after treatment of transcatheter arterial chemo-embolization (TACE) combined with radiofrequency ablation (RFA) by computed tomography (CT) scan is difficult; while 18-fluorodeoxyglucose-positron emission tomography/CT ((18)FDG-PET/CT) has some advantages in this aspect.
  • [MeSH-major] Carcinoma, Hepatocellular / radionuclide imaging. Catheter Ablation. Chemoembolization, Therapeutic. Liver Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16159437.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Faraj W, Deborah Mukherji D, Fakih H, Majzoub N, Khalife M: Liver transplantation in Lebanon: A hard lesson to learn. Ann Transplant; 2010 Jul-Sep;15(3):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in Lebanon: A hard lesson to learn.
  • BACKGROUND: The aim of this study is to review all liver transplants performed at the American University of Beirut Medical Center from 1998 to present.
  • MATERIAL/METHODS: From 1998 to present, 15 liver transplants were performed in our institution.
  • Indications for adult transplants were: 2 alcoholic liver cirrhosis, 2 cryptogenic, hepatitis B, hepatitis C with HCC, 1 subacute liver failure, 1 Budd Chiari syndrome, 1 biliary cirrhosis secondary to iatrogenic common bile duct injury, and 1 multiple hydatid disease of the liver.
  • Pediatric transplant indications were: 2 cryptogenic liver cirrhosis, 1 extrahepatic biliary atresia, 1 familial hypercholesterolemia, and 1 congenital hepatic fibrosis.
  • Of the 14 transplants, 4 were living related liver transplants.
  • The causes of death were: 2 primary non-functions, 1 intraoperative cardiac arrest, 1 portal and hepatic artery thrombosis, and 1 severe cellular rejection.
  • All 9 survivors are well, with normal liver function tests at a median follow-up time of 70 months (range 13-131) after transplantation.
  • Living related liver transplant is an important alternative source of organs, but should not replace cadaveric donation.
  • [MeSH-major] Liver Transplantation / mortality
  • [MeSH-minor] Adult. Biliary Atresia / surgery. Biliary Tract Diseases / etiology. Carcinoma, Hepatocellular / surgery. Cause of Death. Child. Female. Follow-Up Studies. Hepatitis C / surgery. Humans. Lebanon. Liver Cirrhosis / etiology. Liver Cirrhosis / surgery. Liver Function Tests. Liver Neoplasms / surgery. Living Donors / statistics & numerical data. Male. Postoperative Complications / classification. Postoperative Complications / surgery. Retrospective Studies. Survival Rate. Time Factors. Tissue and Organ Procurement

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877263.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


36. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer; 2009 Jan 15;115(2):428-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
  • METHODS: Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles.
  • The majority of patients had transient liver function derangement.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis B / complications. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19107763.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


37. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • Additional risk factors like smoking and HCV co-infection seem to play important roles in the high incidence of lung and hepatocellular carcinomas.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology


38. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J: Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol; 2006 Apr;19(4):533-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma.
  • We studied the association of E-cadherin, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinase with the progression and metastasis of hepatocellular carcinoma.
  • Tissue microarray including six normal livers, 14 cirrhotic livers, 39 macroregenerative nodules, 16 dysplastic nodules, 22 grade I hepatocellular carcinomas, 43 grade II hepatocellular carcinomas, seven grade III hepatocellular carcinomas, and 10 metastatic hepatocellular carcinomas were stained immunohistochemically with antibodies against MMPs -1, -2, -3, -7, -9, tissue inhibitors of metalloproteinase-1, -2, -3, and E-cadherin.
  • Compared with normal liver, cirrhotic liver had significantly lower E-cadherin and tissue inhibitors of metalloproteinase-1 but higher MMP-1 and -7, which suggest a more favorable environment for tumor invasion and metastasis.
  • Grade I and grade II hepatocellular carcinomas demonstrated high E-cadherin and decreased MMP-3 and -9, which may explain the rarity of extrahepatic metastasis in low-grade hepatocellular carcinomas despite the high circulatory volume of the liver.
  • The histological progression from dysplastic nodule to well-differentiated hepatocellular carcinoma and to less differentiated tumors was associated with a gradual decrease in tissue expression of E-cadherin, tissue inhibitors of metalloproteinase-2 and -3.
  • Metastatic hepatocellular carcinomas showed significantly lower level of tissue inhibitors of metalloproteinase-1, -2, -3 but higher level of MMP-7.
  • These data suggest that tissue expression of E-cadherin, certain MMPs, and tissue inhibitors of metalloproteinases could be useful markers to predict the progression and metastasis of hepatocellular carcinoma.
  • [MeSH-major] Cadherins / analysis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Matrix Metalloproteinases / analysis. Tissue Inhibitor of Metalloproteinases / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunohistochemistry. Male. Matrix Metalloproteinase 1 / analysis. Matrix Metalloproteinase 3 / analysis. Matrix Metalloproteinase 7 / analysis. Matrix Metalloproteinase 9 / analysis. Middle Aged. Neoplasm Metastasis. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Tissue Inhibitor of Metalloproteinase-3 / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474379.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Tissue Inhibitor of Metalloproteinases; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


39. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC: Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology; 2010 Dec;52(6):1922-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma.
  • Hepatitis B virus (HBV) is a major etiological factor of hepatocellular carcinoma (HCC).
  • However, the postoperative prognostic value of the virological factors assayed directly from liver tissue has never been investigated.
  • To address this issue, 185 liver samples obtained from the noncancerous part of surgically removed HBV-associated HCC tissues were subjected to virological analysis.
  • Assayed factors included the amount of HBV-DNA in the liver tissues; genotype; and the presence of the HBV precore stop codon G1896A mutation, basal core promoter A1762T/G1764A mutation, and pre-S deletions/stop codon mutation.
  • It was found that an HBV-DNA level >3.0 × 10(7) copies/g of liver tissue and the presence of the basal core promoter mutation independently predicted disease-free (adjusted hazard ratio 1.641 [95% confidence interval (CI) 1.010-2.667] and 2.075 [95% CI 1.203-3.579], respectively) and overall (adjusted hazard ratio 2.807 [95% CI 1.000-7.880] and 5.697 [95% CI 1.678-19.342], respectively) survival.
  • CONCLUSION: The amount of HBV-DNA in liver tissue and the presence of the basal core promoter mutation were two independent predictors for postoperative survival in HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. DNA, Viral / genetics. Hepatitis B Core Antigens / genetics. Hepatitis B Surface Antigens / genetics. Liver / virology. Liver Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Codon, Terminator. Female. Hepatitis B virus / genetics. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Prognosis. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Association for the Study of Liver Diseases.
  • [CommentIn] Hepatology. 2011 Jul;54(1):378 [21469167.001]
  • (PMID = 20814897.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA, Viral; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


40. Nanashima A, Shibata K, Nakayama T, Tobinaga S, Araki M, Kunizaki M, Takeshita H, Hidaka S, Sawai T, Nagayasu T, Yasutake T: Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol; 2009 Aug;16(8):2130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND: Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma.
  • We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC).
  • By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin.
  • Shorter disease-free survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (<5 mm).
  • [MeSH-major] Adenocarcinoma / blood supply. Colorectal Neoplasms / blood supply. Liver Neoplasms / blood supply. Microvessels / pathology. Neoplasm Recurrence, Local / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Female. Follow-Up Studies. Hepatectomy. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Microcirculation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult


41. Pungpapong S, Kim WR, Poterucha JJ: Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc; 2007 Aug;82(8):967-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A dynamic balance between viral replication and host immune response is pivotal to the pathogenesis of liver disease.
  • Of these, HBeAg-positive and HBeAg-negative chronic hepatitis may progress to cirrhosis and its long-term sequelae including hepatic decompensation and hepatocellular carcinoma.
  • These data emphasize the importance of monitoring all patients with chronic HBV infection to identify candidates for and select optimal timing of antiviral treatment, to recognize those at risk of complications, and to implement surveillance for early detection of hepatocellular carcinoma.
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / virology. Carrier State / virology. Hepatitis B Surface Antigens / analysis. Hepatitis B e Antigens / analysis. Hepatitis B virus / immunology. Hepatitis B virus / physiology. Hepatitis B, Chronic / immunology. Hepatitis B, Chronic / physiopathology. Humans. Immune Tolerance / immunology. Infant. Infant, Newborn. Liver Cirrhosis / virology. Liver Neoplasms / virology. Virus Replication / immunology. Virus Replication / physiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673066.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 61617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens
  • [Number-of-references] 123
  •  go-up   go-down


42. Wei YF, Wang HC, Chang YC: Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis. J Formos Med Assoc; 2006 Apr;105(4):346-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis.
  • Hemoperitoneum caused by ruptured hepatocellular carcinoma (HCC) is not uncommon in patients with HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618616.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


43. Goudard Y, Rouquie D, Bertocchi C, Daligand H, Baton O, Lahutte M, Terris B, Baranger B: [Malignant transformation of hepatocellular adenoma in men]. Gastroenterol Clin Biol; 2010 Mar;34(3):168-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of hepatocellular adenoma in men].
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Cell Transformation, Neoplastic / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Cholecystectomy. Hepatectomy / methods. Humans. Male. Treatment Outcome. Weight Loss

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20189337.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


44. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, Prabhakaran PS, Benson AB: A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol; 2005 Jul-Sep;26(3):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
  • The primary objective of this study was to determine the response rates of a combination of gemcitabine and cisplatin in unresectable hepatocellular carcinoma (HCC) in Indian patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512457.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


45. Xi M, Liu MZ, Li QQ, Cai L, Zhang L, Hu YH: [Analysis of abdominal organ motion using four-dimensional CT]. Ai Zheng; 2009 Sep;28(9):989-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The 4DCT scans of 13 patients with hepatocellular carcinoma were analyzed, five of whom had para-aortic lymph node metastases.
  • The liver, kidneys, pancreas, spleen, and para-aortic lymph nodes were contoured in all 10 respiratory phases of 4DCT scans.
  • Analysis of the center of the mass of abdominal organs revealed predominant cranio-caudal (CC) movement, with a mean of (10.1+/-3.9) mm for liver, (9.3+/-2.9) mm for left kidney, (9.6+/-4.1) mm for right kidney, (7.6+/-3.0) mm for pancreas, (10.6+/-3.3) mm for spleen, and (5.7+/-1.8) mm for para-aortic lymph nodes.
  • The CC movement of the liver and the right kidney correlated well with the diaphragmatic movement, and no significant differences were observed.
  • The diaphragmatic mobility can approximate the CC movement of liver and right kidney, and the movement amplitude of para-aortic lymph nodes is much smaller than diaphragmatic mobility.
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Four-Dimensional Computed Tomography / methods. Liver Neoplasms / radiography. Movement. Respiration
  • [MeSH-minor] Adult. Aged. Diaphragm / radiography. Female. Humans. Kidney / radiography. Liver / radiography. Lymph Nodes / radiography. Lymphatic Metastasis. Male. Middle Aged. Pancreas / radiography. Spleen / radiography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728920.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


46. Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH: Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol; 2010 Sep;21(9):1377-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
  • PURPOSE: Patients with portal vein thrombosis (PVT) and hepatocellular carcinoma (HCC) have limited treatment options because of increased disease burden and diminished hepatic perfusion.
  • Cancer of the Liver Italian Program (CLIP) scores ranged from 2 to 5, with 18% of patients having a score of 4 or greater.

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Portal vein thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Hepatology. 2000 Aug;32(2):233-8 [10915729.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2266-73 [11147597.001]
  • [Cites] Gut. 2002 Jun;50(6):881-5 [12010894.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211-21 [12354839.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] J Vasc Interv Radiol. 2004 Apr;15(4):335-45 [15064336.001]
  • [Cites] J Nucl Med. 1971 Mar;:Suppl 5:5-23 [5551700.001]
  • [Cites] J Vasc Interv Radiol. 1993 May-Jun;4(3):347-51 [8513208.001]
  • [Cites] Eur J Nucl Med. 1997 Mar;24(3):293-8 [9143467.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(7):397-400 [9719503.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2419-26 [15822130.001]
  • [Cites] Am J Gastroenterol. 2005 Sep;100(9):1995-2004 [16128944.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1653-9 [16371532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Jul-Aug;29(4):522-9 [16729228.001]
  • [Cites] J Vasc Interv Radiol. 2006 Aug;17(8):1251-78 [16923973.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7561-7 [17171782.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13-23 [17448867.001]
  • [Cites] Dig Dis Sci. 2007 Nov;52(11):3290-5 [17394062.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] Drugs. 2008;68(2):251-8 [18197728.001]
  • [Cites] Oncology. 2007;72(3-4):188-93 [18097170.001]
  • [Cites] Liver Int. 2009 Jan;29(1):74-81 [18331238.001]
  • [Cites] J Am Coll Surg. 2009 Mar;208(3):375-82 [19317999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1494-500 [19157721.001]
  • (PMID = 20691606.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA118431-02; United States / NCI NIH HHS / CA / CA118431-04; United States / NCI NIH HHS / CA / K23 CA118431-05; United States / NCI NIH HHS / CA / K23 CA118431; United States / NCI NIH HHS / CA / K23 CA118431-01A1; United States / NCI NIH HHS / CA / CA118431-02; United States / NCI NIH HHS / CA / CA118431-03; United States / NCI NIH HHS / CA / K23 CA118431-04; United States / NCI NIH HHS / CA / CA118431-05; United States / NCI NIH HHS / CA / K23 CA118431-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ NIHMS227449; NLM/ PMC2945527
  •  go-up   go-down


47. Zhang FJ, Li CX, Zhang L, Wu PH, Jiao DC, Duan GF: Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma. Cancer Biol Ther; 2009 Apr;8(7):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.
  • OBJECTIVE: To evaluate the safety and short- to mid-term efficacy of CT-guided (125)I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma (HCC).
  • RESULTS: Among the ten patients, one died of liver failure 15 months and one of renal failure 29 months after brachytherapy.
  • METHODS: From November 2004-May 2008, ten patients with intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for HCC underwent (125)I brachytherapy under the guidance of computed tomography.
  • CONCLUSION: CT-guided (125)I brachytherapy is a safe and effective therapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Hepatocellular / radiotherapy. Iodine Radioisotopes / administration & dosage. Liver Neoplasms / radiotherapy. Liver Transplantation / methods. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Female. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Radiotherapy Dosage. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Apr;8(7):22-4 [19417558.001]
  • (PMID = 19276683.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


48. Kobayashi T, Hayashi T, Funabasama S, Tsukagoshi S, Minami M, Moriyama N: Three-dimensional perfusion imaging of hepatocellular carcinoma using 256-slice multidetector-row computed tomography. Radiat Med; 2008 Nov;26(9):557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional perfusion imaging of hepatocellular carcinoma using 256-slice multidetector-row computed tomography.
  • PURPOSE: The aim of this study was to evaluate the clinical capability of three-dimensional (3D) perfusion imaging of hepatocellular carcinoma (HCC) by performing dynamic scanning using a 256-slice multidetector-row CT (MDCT) scanner.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnostic imaging. Liver Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Predictive Value of Tests. Radiographic Image Enhancement / methods. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 2003 Nov-Dec;21(6):246-51 [14743897.001]
  • [Cites] Br J Radiol. 1991 May;64(761):409-12 [2036562.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):969-76 [10587130.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):253-6 [15972432.001]
  • [Cites] Clin Sci (Lond). 2000 Dec;99(6):517-25 [11099395.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):667-73 [11222202.001]
  • [Cites] Radiology. 1993 Aug;188(2):405-11 [8327686.001]
  • [Cites] Acad Radiol. 2004 Feb;11(2):215-23 [14974597.001]
  • [Cites] Acta Radiol. 2004 Nov;45(7):709-15 [15624511.001]
  • (PMID = 19030966.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


49. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF: Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol; 2008 Aug;67(2):336-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors.
  • PURPOSE: To investigate the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), and the prognostic factors for post-RFA survival rate.
  • Nine potential factors were found with significant effects on survival rate, and they were number of tumors, location of tumors, pre-RFA liver function enzymes, Child-Pugh classification, AJCC staging, primary or recurrent HCC, tumor pathological grading, using mathematical protocol in RFA procedure and tumor necrosis 1 month after RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765421.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


50. Iwamoto A, Ikeguchi M, Matsumoto S, Hukumoto Y, Inoue M, Ozaki T, Ataka M, Tanida T, Endo K, Katano K, Hirooka Y: Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori; 2006 Mar-Apr;92(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
  • AIMS AND BACKGROUND: In several neoplastic diseases including hepatocellular carcinoma (HCC) immunosuppression is correlated with disease stage, progression and outcome.
  • The present study analyzed the correlation between local immune responses and COX-2 gene expression levels in patients with primary HCCs.
  • The COX-2 gene expression levels were quantified by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and compared with the CD8+ T cell densities detected by immunohistochemistry.
  • The CD8+ T cell density in COX-2-expressing tumors (6.1 cells/high-power field (HPF), x200 magnification) was suppressed compared with that in non-COX-2-expressing tumors (13.6 cells/HPF, P = 0.009).
  • CONCLUSIONS: Elevation of the tumor COX-2 level is correlated with the suppression of local immune responses in HCCs, suggesting that COX-2 plays a role in early tumor recurrence in the residual liver in patients after HCC resection.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / immunology. Cyclooxygenase 2 / metabolism. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD8-Positive T-Lymphocytes / immunology. Disease-Free Survival. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724692.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


51. García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V, Génova R, Alvarez E: Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol Hepatol; 2009 Aug;21(8):895-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although hepatitis C and hepatitis B virus (HCV/HBV) infections are an important health problem worldwide, their burden of disease (BoD) taking into account their chronic consequences, cirrhosis, and hepatocellular carcinoma (HCC), is still unknown.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality. Liver Cirrhosis / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Sex Distribution. Spain / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357523.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


52. Jiang YY, Wang XY, Guo XM, Jiang XX: [Small hepatocellular carcinoma in patients with hepatitis B-induced cirrhosis: a comparison between MRI and MDCT]. Beijing Da Xue Xue Bao; 2010 Dec 18;42(6):767-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small hepatocellular carcinoma in patients with hepatitis B-induced cirrhosis: a comparison between MRI and MDCT].
  • OBJECTIVE: To compare efficacy of plain and contrast enhancement MRI (1.5T or 3T) and dynamic contrast enhanced multidetector CT (MDCT, 16- or 64 -slice) for the detection of small hepatocellular carcinoma (HCC) in patients with hepatitis B-induced cirrhosis.
  • METHODS: A total of 21 patients (18 men, 3 women; age range, 44-74 years) with 22 small HCC and liver cirrhosis were enrolled, all having undergone MDCT and MRI within one month.
  • [MeSH-major] Hepatitis B, Chronic / complications. Liver Cirrhosis / complications. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, Spiral Computed
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Contrast Media. Female. Humans. Image Enhancement / methods. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21170112.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


53. Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM: Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J; 2006 Dec 31;47(6):793-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC).
  • However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC.
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Korea. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 1998 Sep-Oct;5(5):1171-4 [9683829.001]
  • [Cites] J Korean Med Sci. 1998 Jun;13(3):306-10 [9681811.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] Hepatology. 1999 May;29(5):1596-601 [10216148.001]
  • [Cites] J Viral Hepat. 1999 Sep;6(5):411-3 [10607258.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):58-65 [10618606.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3216-22 [10626189.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):196-7 [11213099.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S114-20 [12407584.001]
  • [Cites] J Viral Hepat. 2003 Nov;10(6):437-45 [14633177.001]
  • [Cites] Lancet. 2003 Dec 20;362(9401):2095-100 [14697814.001]
  • [Cites] Ann Intern Med. 2004 Mar 2;140(5):346-55 [14996676.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S294-302 [15508097.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1906-11 [1454085.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1426-32 [9807989.001]
  • (PMID = 17191307.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  • [Other-IDs] NLM/ PMC2687818
  •  go-up   go-down


54. Schrem H, Till N, Becker T, Bektas H, Manns MP, Strassburg CP, Klempnauer J: [Long-term results after liver transplantation]. Chirurg; 2008 Feb;79(2):121-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after liver transplantation].
  • Liver transplantation has been reported to reach excellent results for selected indications.
  • We analysed the results of liver transplantation in our centre over a period of 23 years, with a total of 2,114 consecutive liver transplants in 1,773 patients (eras I-III 5.5 years each, era IV 6.5 years).
  • Overall 20-year survival after liver transplantation was 29.8%.
  • Both long-term patient and graft survival were significantly better after primary liver transplantation than after first retransplantation (P<0.001).
  • In era IV, the most recent, 5-year patient survival reached 96% for PBC, 89.4% for PSC, 78.5% for biliary atresia, 70% for acute liver failure, 69.1% for HBV-related cirrhosis, 61.3% for hepatocellular carcinoma, and 56% for HCV-related cirrhosis.
  • [MeSH-major] Liver Failure / surgery. Liver Neoplasms / surgery. Liver Transplantation. Postoperative Complications / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Child. Child, Preschool. Diffusion of Innovation. Female. Follow-Up Studies. Germany. Graft Survival. Humans. Infant. Male. Middle Aged. Prognosis. Reoperation. Retrospective Studies. Survival Rate. Systemic Inflammatory Response Syndrome / etiology. Systemic Inflammatory Response Syndrome / mortality

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):538-42 [15056099.001]
  • [Cites] Clin Transplant. 2006 Sep-Oct;20(5):617-23 [16968488.001]
  • [Cites] Transplant Proc. 2004 Nov;36(9):2525-31 [15621081.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):997-1000 [12861525.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1452-9 [16315310.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):411-20 [9742924.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):931-7 [17383422.001]
  • [Cites] Transplant Proc. 2001 Nov-Dec;33(7-8):3433-5 [11750470.001]
  • [Cites] Hepatogastroenterology. 2007 Jun;54(76):1181-6 [17629066.001]
  • [Cites] Liver Transpl. 2006 Jan;12(1):2-11 [16382451.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99 [15979889.001]
  • [Cites] Liver Transpl. 2003 May;9(5):527-32 [12740799.001]
  • [Cites] Transplantation. 2005 May 15;79(9):1206-9 [15880071.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):490-500 [10998647.001]
  • [Cites] Exp Clin Transplant. 2004 Jun;2(1):178-82 [15859925.001]
  • [Cites] Pediatr Transplant. 2007 Sep;11(6):661-70 [17663691.001]
  • [Cites] Transplantation. 2002 Mar 27;73(6):941-7 [11923697.001]
  • [Cites] Ann Surg. 2003 May;237(5):666-75; discussion 675-6 [12724633.001]
  • [Cites] Arch Surg. 2005 Mar;140(3):273-7 [15781792.001]
  • [Cites] Transplantation. 2004 Jan 27;77(2):226-31 [14742986.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1370-8 [16771963.001]
  • [Cites] Langenbecks Arch Chir. 1988;373(2):127-30 [3287073.001]
  • [Cites] Liver Transpl. 2007 May;13(5):733-40 [17370330.001]
  • [Cites] Liver Transpl. 2004 Dec;10(12):1441-53 [15558590.001]
  • [Cites] Ann Surg. 2005 Jun;241(6):905-16; discussion 916-8 [15912040.001]
  • [Cites] Liver Transpl. 2001 Sep;7(9):811-5 [11552217.001]
  • [Cites] Transplantation. 2001 Sep 27;72(6):1113-22 [11579310.001]
  • (PMID = 18209988.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 38
  •  go-up   go-down


55. Alvarado-Esquivel C, Arellano-Santos CV, Salazar-Arana JL, Mercado-Suárez MF: [Prevalence of hepatitis B virus infection in patients suffering from acute and chronic liver disease in three public hospitals in Durango, Mexico]. Gac Med Mex; 2006 Nov-Dec;142(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence of hepatitis B virus infection in patients suffering from acute and chronic liver disease in three public hospitals in Durango, Mexico].
  • OBJECTIVE: We carried out an observational, descriptive, and retrospective epidemiological study in order to determine the prevalence of hepatitis B virus infection (HBV) in patients with acute and chronic liver disease in three public hospitals of Durango, Mexico.
  • MATERIAL AND METHODS: Sixty five adult patients were included in the study.
  • Twenty three patients suffered from acute hepatitis, 10 chronic hepatitis, 29 liver cirrhosis, 2 hepatocellular carcinoma, and I fulminant hepatitis.
  • Of the two positive cases, one had chronic hepatitis and other liver cirrhosis.
  • CONCLUSION: We concluded that the prevalence of HBV infection in patients with liver disease in the city of Durango is low.
  • [MeSH-minor] Adult. Female. Hepatitis B virus / isolation & purification. Humans. Male. Mexico / epidemiology. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Socioeconomic Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201106.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


56. Kakizaki S, Takagi H, Yamazaki Y, Sohara N, Sato K, Nagamine T, Mori M: Different outcomes of nosocomial infection with hepatitis C virus from the same origin. World J Gastroenterol; 2006 Jan 28;12(4):659-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The outcome of infection with hepatitis C virus (HCV) varies substantially from self-limiting infection to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma among the individuals.
  • [MeSH-minor] Adult. Aged. Female. Genotype. HLA-DQ Antigens / genetics. HLA-DQ beta-Chains. HLA-DR Antigens / genetics. HLA-DRB1 Chains. Hepacivirus / classification. Hepacivirus / genetics. Hepatitis C Antibodies / blood. Humans. Male. Viral Envelope Proteins / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Dec 18-25;354(9196):2119-24 [10609818.001]
  • [Cites] J Med Virol. 2001 Nov;65(3):505-9 [11596085.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):993-1000 [12297849.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1899-905 [1280771.001]
  • [Cites] Semin Liver Dis. 1995 Feb;15(1):15-32 [7597442.001]
  • [Cites] Ann Intern Med. 1999 Jan 19;130(2):130-4 [10068359.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):706-14 [8698862.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S [9305658.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):21S-28S [9305659.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1675-81 [9352872.001]
  • [Cites] Lancet. 1998 Jan 31;351(9099):351-5 [9652633.001]
  • [Cites] Semin Liver Dis. 1995 Feb;15(1):5-14 [7597444.001]
  • (PMID = 16489688.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / E1 protein, Hepatitis C virus; 0 / HLA-DQ Antigens; 0 / HLA-DQ beta-Chains; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains; 0 / Hepatitis C Antibodies; 0 / Viral Envelope Proteins
  • [Other-IDs] NLM/ PMC4066107
  •  go-up   go-down


57. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP: CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol); 2007 Apr;19(3):204-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD117 (c-kit) expression in human hepatocellular carcinoma.
  • AIMS: Although various methods of treatment have been tried, treatment options for advanced hepatocellular carcinoma (HCC) remain limited.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Benzamides. Child. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Piperazines / pharmacology. Piperazines / therapeutic use. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359908.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


58. Chen MH, Wei Y, Yan K, Gao W, Dai Y, Huo L, Yin SS, Zhang H, Poon RT: Treatment strategy to optimize radiofrequency ablation for liver malignancies. J Vasc Interv Radiol; 2006 Apr;17(4):671-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy to optimize radiofrequency ablation for liver malignancies.
  • PURPOSE: The purposes of this study were to investigate a treatment strategy to increase liver tumor necrosis and minimize complications with ultrasound-guided percutaneous radiofrequency (RF) ablation and to evaluate its therapeutic efficacy.
  • MATERIALS AND METHODS: A total of 332 patients with 503 liver malignancies underwent RF ablation according to a mathematical protocol with adjunctive measures.
  • In the 332 patients, 205 had 308 hepatocellular carcinomas (HCCs) with a mean largest diameter of 4.1 cm and 127 had 195 metastatic liver carcinomas (MLCs) with a mean largest diameter of 3.9 cm.
  • Some adjunctive measures such as supplementary fine needle localization, local saline solution injection, and feeding vessel ablation were used to deal with different features of these liver tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome. Ultrasonography, Doppler, Color. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614151.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kita Y, Klintmalm G, Kobayashi S, Yanaga K: Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci; 2007 Dec;52(12):3392-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatitis B, Chronic / complications. Liver Cirrhosis / complications. Liver Neoplasms / surgery. Liver Transplantation / pathology
  • [MeSH-minor] Adult. Biopsy. Follow-Up Studies. Humans. Male. Recurrence. Reoperation. Tomography, X-Ray Computed. Transplantation, Homologous


60. Haute Autorité de Santé: [Indications for hepatic transplantation -- January 19 and 20, 2005, Lyon (Palais des congrès)]. J Chir (Paris); 2005 May-Jun;142(3):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Liver Transplantation
  • [MeSH-minor] AIDS-Related Opportunistic Infections / surgery. Adult. Age Factors. Aged. Carcinoma, Hepatocellular / surgery. Child. France. HIV Infections / surgery. Hepatitis B / surgery. Hepatitis C / surgery. Hepatitis, Viral, Human / surgery. Humans. Immunosuppressive Agents / therapeutic use. Liver Cirrhosis, Alcoholic / surgery. Liver Neoplasms / surgery. Living Donors. Meta-Analysis as Topic. Middle Aged. Postoperative Care. Preoperative Care. Prognosis. Randomized Controlled Trials as Topic. Reoperation. Risk Factors. Tissue Donors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142083.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; Consensus Development Conference; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 0
  •  go-up   go-down


61. Kusano T, Sasaki A, Kai S, Endo Y, Iwaki K, Shibata K, Ohta M, Kitano S: Predictors and prognostic significance of operative complications in patients with hepatocellular carcinoma who underwent hepatic resection. Eur J Surg Oncol; 2009 Nov;35(11):1179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and prognostic significance of operative complications in patients with hepatocellular carcinoma who underwent hepatic resection.
  • AIMS: The morbidity rate of hepatic resection for hepatocellular carcinoma (HCC) remains high.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Intraoperative Complications / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Logistic Models. Male. Middle Aged. Postoperative Complications / mortality. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443173.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Liu YQ, Poon RT, Hughes J, Li QY, Yu WC, Fan ST: Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol; 2005 Jan 14;11(2):164-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma.
  • AIM: Despite the presence of lymphocyte infiltration, human hepatocellular carcinoma (HCC) is typically a rapidly progressive disease.
  • In this study, we investigated various factors regulating T cell migration in HCC patients.
  • We examined serum CXC chemokine levels in HCC patients and demonstrated the production of CXC chemokines by HCC cell lines.
  • We determined the effect of both HCC patient serum and tumor cell conditioned supernatant upon lymphocyte expression of chemokine receptor CXCR3 as well as lymphocyte migration.
  • RESULTS: Increased levels of IP-10 and Mig were detected in HCC patient serum and culture supernatants of HCC cell lines.
  • The IP-10 concentration in the tumor was significantly higher than that in the non-involved adjacent liver tissues.
  • HCC cell lines secreted functional chemokines that induced a CXCR3-specific chemotactic response of lymphocytes.
  • Furthermore, tumor-cell-derived chemokines induced initial rapid phosphorylation of lymphocyte ERK followed by later inhibition of ERK phosphorylation.
  • The culture of normal lymphocytes with HCC cell line supernatants or medium containing serum from HCC patients resulted in a significant reduction in the proportion of lymphocytes exhibiting surface expression of CXCR3.
  • The reduction in T cell expression of CXCR3 resulted in reduced migration toward the ligand IP-10, and both CD4+ and CD8+ T cells from HCC patients exhibited diminished chemotactic responses to IP-10 in vitro compared to T cells from healthy control subjects.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Liver Neoplasms / immunology. Receptors, Chemokine / blood. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Chemokines / analysis. Chemotaxis, Leukocyte. Female. Humans. Ligands. Male. Middle Aged. Receptors, CXCR3. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633209.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCR3 protein, human; 0 / Chemokines; 0 / Ligands; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine
  • [Other-IDs] NLM/ PMC4205395
  •  go-up   go-down


63. Sanz-Cameno P, Martín-Vílchez S, Lara-Pezzi E, Borque MJ, Salmerón J, Muñoz de Rueda P, Solís JA, López-Cabrera M, Moreno-Otero R: Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol; 2006 Oct;169(4):1215-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein.
  • To analyze how HBV induces vascular growth and remodeling in vivo, we assessed the expression of angiopoietin-2 (Ang2) in liver biopsies from CHB patients by reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry because of the relevant role of Ang2 in vascular development, remodeling, and tumor promotion.
  • In addition, we analyzed the influence of HBx in the expression of Ang2 in HBx-expressing hepatocyte cell lines and in hepatic stellate cells stimulated with conditional medium from HBx-hepatocytes.
  • Ang2 expression was clearly up-regulated at both mRNA and protein levels in the liver of CHB patients, showing an intense staining of inflammatory infiltrates and vascular structures at inflamed portal areas.
  • Therefore, HBx could account for the induction of Ang2 observed in CHB, especially the 50-kd form, contributing to pathological angiogenesis and hepatocellular carcinoma progression.
  • [MeSH-major] Angiopoietin-2 / metabolism. Hepatitis B virus / pathogenicity. Hepatitis B, Chronic / metabolism. Liver / metabolism. Trans-Activators / physiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Cell Line. Female. Hepatocytes / chemistry. Hepatocytes / metabolism. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Male. Middle Aged. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ Res. 1998 Aug 10;83(3):233-40 [9710115.001]
  • [Cites] Nat Med. 2006 Feb;12(2):235-9 [16462802.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1253-7 [10217098.001]
  • [Cites] Nat Med. 1999 May;5(5):495-502 [10229225.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):124-31 [15629517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):175-9 [15611471.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):209-18 [15690074.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):233-5 [16290311.001]
  • [Cites] Hepatology. 2000 Jan;31(1):141-8 [10613739.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):456-61 [10679226.001]
  • [Cites] Pharmacol Rev. 2000 Jun;52(2):237-68 [10835101.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18550-6 [10766762.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):257-67 [11283723.001]
  • [Cites] Hepatology. 2001 Jul;34(1):82-8 [11431737.001]
  • [Cites] J Clin Invest. 2001 Jul;108(1):39-40 [11435455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10 [12163646.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1831-8 [12488433.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G373-84 [12388200.001]
  • [Cites] Hepatology. 2003 Mar;37(3):674-85 [12601365.001]
  • [Cites] Hepatology. 2003 May;37(5):1105-13 [12717391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5028-33 [12692304.001]
  • [Cites] Science. 1991 May 10;252(5007):842-4 [1827531.001]
  • [Cites] Nature. 1991 May 23;351(6324):317-20 [2034275.001]
  • [Cites] Science. 1996 Apr 5;272(5258):60-6 [8600538.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7151-8 [9054410.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8162-7 [9223332.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1343-52 [9525976.001]
  • [Cites] J Biosci. 2003 Apr;28(3):311-21 [12734409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9 [12861074.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35501-7 [12816951.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1187-95 [14513066.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39076-84 [12855680.001]
  • [Cites] FASEB J. 2003 Nov;17(14):2115-7 [12958148.001]
  • [Cites] FASEB J. 2004 Feb;18(2):382-4 [14688211.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):81-91 [15018892.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12171-80 [14702352.001]
  • [Cites] Mol Cancer Res. 2004 Mar;2(3):159-69 [15037655.001]
  • [Cites] J Hepatol. 2004 May;40(5):799-807 [15094228.001]
  • [Cites] Hepatology. 2004 May;39(5):1185-95 [15122744.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Nat Med. 2006 Feb;12(2):171-2 [16462798.001]
  • [Cites] J Clin Invest. 1999 Feb;103(3):341-5 [9927494.001]
  • (PMID = 17003480.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / hepatitis B virus X protein
  • [Other-IDs] NLM/ PMC1698851
  •  go-up   go-down


64. Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL: [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):630-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC).
  • METHODS: During the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid).
  • The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50).
  • CONCLUSION: Soafenib is effective for unresectable primary HCC with tolerable toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Chemoembolization, Therapeutic / methods. Diarrhea / chemically induced. Disease Progression. Follow-Up Studies. Humans. Hypertension / chemically induced. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Skin Diseases / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122420.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


65. Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L: A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs; 2008 Aug;26(4):381-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
  • Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients.
  • Responses were four stable disease, 14 progressive disease, and three not evaluable: two had early toxicities (renal/liver failure, sepsis) and one was noncompliant.
  • Thirteen patients died on-study: 12 PD and one liver failure; none were drug-related.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone / therapeutic use. Disease Progression. Female. Folic Acid / therapeutic use. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pemetrexed. Survival Rate. Treatment Outcome. Vitamin B 12 / therapeutic use

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Chemotherapy. 2008;54(1):1-8 [18063861.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):56-62 [15655939.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24 [15508087.001]
  • [Cites] World J Gastroenterol. 2007 Dec 28;13(48):6553-7 [18161926.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1955-60 [9951847.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):427-32 [10501918.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8 [16803502.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2675-83 [17473199.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25 [17103105.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):578-86 [15274071.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3652-9 [17575230.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):395-9 [9815697.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):421-7 [11905412.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):409-18 [15231247.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):105-10 [10412943.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1213-6 [2446752.001]
  • [Cites] J Clin Gastroenterol. 2007 Oct;41(9):839-54 [17881931.001]
  • (PMID = 18305899.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 7S5I7G3JQL / Dexamethasone; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


66. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC, Lee KT: Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol; 2007 Jun;60(6):642-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma.
  • However, its potential roles and biological effects in hepatocellular carcinoma (HCC) are not well established.
  • Using a semiquantitative immunohistochemical staining method, the expression patterns of p-STAT3 (tyr705) in both HCC lesions and the adjacent non-tumorous liver parenchyma were analysed.
  • RESULTS: A strong p-STAT3 (tyr705) nuclear staining was observed in 49.3% of HCC lesions, but was reported only in 5.8% of the adjacent non-tumorous liver parenchyma (p<0.001).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2093-8 [12957465.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):978-80 [14523032.001]
  • [Cites] Virology. 2004 Apr 25;322(1):51-60 [15063116.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):630-5 [15350351.001]
  • [Cites] J Med Invest. 2004 Aug;51(3-4):202-9 [15460907.001]
  • [Cites] Hepatology. 1995 May;21(5):1443-9 [7737651.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1379-83 [8910279.001]
  • [Cites] J Viral Hepat. 1996 Nov;3(6):277-83 [8947878.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):741-3 [15655835.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1386-93 [15746037.001]
  • [Cites] World J Gastroenterol. 2005 Mar 21;11(11):1705-8 [15786555.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):860-9 [15761498.001]
  • [Cites] J Dermatol. 2005 May;32(5):354-60 [16043897.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 23;335(2):292-9 [16081048.001]
  • [Cites] Cell Mol Immunol. 2005 Apr;2(2):92-100 [16191414.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jun;2(6):315-24 [16264989.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):357-68 [10824878.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):265-9 [10982625.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9599-604 [11481452.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7721-30 [11604508.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584.001]
  • [Cites] World J Gastroenterol. 2001 Feb;7(1):33-6 [11819729.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28411-7 [12032149.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):641-53 [12208879.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8 [12394209.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):319-29 [12545153.001]
  • [Cites] J Biosci. 2003 Apr;28(3):311-21 [12734409.001]
  • [Cites] Hepatology. 2003 Jul;38(1):218-29 [12830005.001]
  • [Cites] Cancer Lett. 2003 Sep 10;199(1):83-9 [12963127.001]
  • [Cites] J Cell Physiol. 2003 Nov;197(2):157-68 [14502555.001]
  • [Cites] Nat Med. 2004 Feb;10(2):168-74 [14716305.001]
  • (PMID = 16901975.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor
  • [Other-IDs] NLM/ PMC1955084
  •  go-up   go-down


67. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology; 2008 Dec;135(6):1972-83, 1983.e1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pivotal role of mTOR signaling in hepatocellular carcinoma.
  • BACKGROUND & AIMS: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscored the importance of pathway characterization to identify novel molecular targets for treatment.
  • Effects of dual blockade of mTOR signaling using a rapamycin analogue (everolimus) and an epidermal/vascular endothelial growth factor receptor inhibitor (AEE788) were evaluated in liver cancer cell lines and in a xenograft model.
  • RICTOR-specific siRNA down-regulation reduced tumor cell viability in vitro.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Mar 8;26(11):1616-25 [16953221.001]
  • [Cites] Hepatology. 2007 Apr;45(4):938-47 [17393520.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3509-12 [17179228.001]
  • [Cites] J Hepatol. 2007 May;46(5):840-8 [17321636.001]
  • [Cites] Nat Med. 2007 Jun;13(6):748-53 [17496901.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6779-88 [18701503.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1379-85 [10723128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Jul;74(7):3065-7 [197531.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3181-5 [10340391.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4272-6 [16015705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2950-2 [16331247.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47 [16696801.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1758-67 [17087938.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Transplantation. 2007 Feb 27;83(4):425-32 [17318075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4457-65 [11494141.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1929-40 [12673720.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1005-14 [15057740.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Hepatology. 2004 Sep;40(3):667-76 [15349906.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50 [15508101.001]
  • [Cites] J Biol Chem. 2007 Aug 31;282(35):25604-12 [17599906.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11712-20 [18089801.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • (PMID = 18929564.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK037340-22; United States / NIDDK NIH HHS / DK / R01 DK076986-01; United States / NIDDK NIH HHS / DK / 1R01DK076986-01; United States / NIDDK NIH HHS / DK / R01 DK037340-22; United States / NIDDK NIH HHS / DK / R01 DK076986; United States / NIDDK NIH HHS / DK / 1R01DK37340-23; United States / NIDDK NIH HHS / DK / R01 DK037340; United States / NIDDK NIH HHS / DK / DK076986-01
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse
  • [Other-IDs] NLM/ NIHMS83434; NLM/ PMC2678688
  •  go-up   go-down


68. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A: Survival and complications in thalassemia. Ann N Y Acad Sci; 2005;1054:40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma can complicate the course of hepatitis.
  • [MeSH-minor] Adolescent. Adult. Blood Transfusion / adverse effects. Bone Diseases, Metabolic / epidemiology. Bone Diseases, Metabolic / etiology. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / mortality. Cardiomyopathies / etiology. Cardiomyopathies / mortality. Cause of Death. Chelation Therapy. Child. Child, Preschool. Cohort Studies. Diabetes Mellitus / epidemiology. Disease-Free Survival. Female. Ferritins / analysis. Hepatitis C / complications. Hepatitis C / epidemiology. Humans. Hypogonadism / epidemiology. Hypogonadism / etiology. Infant. Infant, Newborn. Iron Overload / etiology. Iron Overload / mortality. Italy / epidemiology. Life Expectancy. Liver Neoplasms / etiology. Liver Neoplasms / mortality. Male. Mortality / trends. Multicenter Studies as Topic. Osteoporosis / epidemiology. Osteoporosis / etiology. Pregnancy. Pregnancy Complications, Hematologic. Prevalence

  • Genetic Alliance. consumer health - Thalassemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339650.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-73-2 / Ferritins
  • [Number-of-references] 20
  •  go-up   go-down


69. Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Morishita S, Takamori H, Chikamoto A, Kanemitsu K, Yamashita Y: Evaluation of extrahepatic perfusion of anticancer drugs in the right gastric arterial region on fused images using combined CT/SPECT: is extrahepatic perfusion predictive of gastric toxicity? Cardiovasc Intervent Radiol; 2007 May-Jun;30(3):392-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatic arterial infusion (HAI) chemotherapy is effective for treating primary and metastatic carcinomas of the liver.
  • METHODS: We studied 41 patients with primary or metastatic carcinoma of the liver who received HAI chemotherapy consisting of 5-fluorouracil and cisplatin.
  • [MeSH-major] Angiography. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Hepatocellular / blood supply. Catheters, Indwelling. Image Processing, Computer-Assisted. Infusions, Intra-Arterial. Liver Neoplasms / blood supply. Stomach / blood supply. Stomach / drug effects. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Duodenum / blood supply. Endoscopy, Digestive System. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Stomach Ulcer / chemically induced. Stomach Ulcer / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225975.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Cheung ST, Ho JC, Leung KL, Chen X, Fong DY, So S, Fan ST: Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy. Neoplasia; 2005 Feb;7(2):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy.
  • BACKGROUND: We have previously reported on the cDNA microarray gene expression profiles of hepatocellular carcinomas (HCCs).
  • Among the genes that show prognostic significance and are overexpressed in tumor compared with adjacent nontumorous liver, transcript AA454543 may have potential for practical use.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Hepatectomy. Liver Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Expressed Sequence Tags / metabolism. Female. Humans. Male. Microarray Analysis. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):35-50, viii [12735128.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15089-94 [11752456.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):365-71 [11726920.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3037-44 [11408499.001]
  • [Cites] Hepatology. 2001 Apr;33(4):832-40 [11283847.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Hepatology. 2001 Mar;33(3):676-91 [11230749.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] Hepatology. 2002 May;35(5):1134-43 [11981763.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1929-39 [12058060.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3971-9 [12124329.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4711-21 [12183430.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 1;30(21):4761-9 [12409467.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):835-47 [12695777.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Langenbecks Arch Surg. 2000 Apr;385(3):171-8 [10857487.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Cancer. 1950 Jan;3(1):32-5 [15405679.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1028-36 [9506346.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2443-8 [8625069.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):28-34; discussion 34-5 [7817995.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):375-84 [8385442.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):882-90 [15105181.001]
  • [Cites] Hepatology. 2004 Apr;39(4):944-53 [15057898.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):215-9 [15050913.001]
  • [Cites] Med J Aust. 2003 Aug 18;179(4):212-6 [12914514.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4196-203 [12874026.001]
  • (PMID = 15810144.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1501123
  •  go-up   go-down


71. Romero Marrero C, Ortiz AP, Pérez CM, Pérez J, Torres EA: Survival of hepatocellular carcinoma in Puerto Rico. P R Health Sci J; 2009 Jun;28(2):105-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of hepatocellular carcinoma in Puerto Rico.
  • BACKGROUND: Blacks and Hispanics in the United States (US) have the lowest survival rates of hepatocellular carcinoma (HCC), mainly associated to the presence of advanced disease at diagnosis when intervention is least beneficial.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Puerto Rico / epidemiology. Registries. Risk. Statistics, Nonparametric. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):235-51, vi [15831271.001]
  • [Cites] Int J Epidemiol. 2005 Jun;34(3):593-9 [15802378.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5 [16431312.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1752-63 [18471552.001]
  • [Cites] Arch Intern Med. 2007 Oct 8;167(18):1983-9 [17923599.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2535-42 [14638360.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • (PMID = 19530551.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / R25 RR017589-08; United States / NCRR NIH HHS / RR / R25 RR17589; United States / NCI NIH HHS / CA / U54 CA096297; United States / NCRR NIH HHS / RR / R25 RR017589; United States / NCCDPHP CDC HHS / DP / U58 DP000782; United States / NCRR NIH HHS / RR / G12 RR003051; United States / NCI NIH HHS / CA / U54 CA096297-07; United States / NCRR NIH HHS / RR / G12RR03051; United States / NCRR NIH HHS / RR / G12 RR003051-24; United States / NIMHD NIH HHS / MD / G12 MD007600; United States / NCCDPHP CDC HHS / DP / U58DP000782-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS209148; NLM/ PMC3861879
  •  go-up   go-down


72. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ: Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr; 2010 Jul;34(4):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
  • OBJECTIVES: To evaluate the diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) for the characterization of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) in cirrhotic liver, compared with contrast material-enhanced magnetic resonance imaging (CE-MRI).
  • The signal intensity (SI) of the lesions were classified as low, iso-, slightly high, and strongly high SI compared with that of the surrounding liver parenchyma on DWI for qualitative assessment.
  • Apparent diffusion coefficients (ADCs) and lesion-to-liver ADC ratio of HCCs and DNs were measured and compared by using the Mann-Whitney U test.
  • Combined with CE-MRI, DWI allows improved characterization of HCC versus DN in cirrhotic liver.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Diffusion Magnetic Resonance Imaging / methods. Liver Cirrhosis / complications. Liver Cirrhosis / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Liver / pathology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Observer Variation. ROC Curve. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657216.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


73. Holt A, Wagman LD, Senthil M, McKenzie S, Marx H, Chen YJ, Vora N, Kim J: Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center. Am Surg; 2010 Oct;76(10):1079-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center.
  • Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC).
  • Liver treatment was either lobar or tumor-targeted.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Embolization, Therapeutic / methods. Liver Neoplasms / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105614.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


74. Verwer BJ, Bouma G, Bloemena E, Schreuder TC, Mulder CJ, van Nieuwkerk KM: [Diagnosis and treatment of autoimmune hepatitis]. Ned Tijdschr Geneeskd; 2009;153:A247
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second patient, a 48-year-old woman, had hepatocellular carcinoma in a cirrhotic liver, based on AIH.
  • The third patient was an 81-year-old man with impaired liver function and cirrhosis.
  • No curative therapy for AIH is yet available, but appropriate management of the disease can prolong survival, improve the quality of life, and avoid the need for liver transplantation.
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Liver Transplantation. Male. Middle Aged. Quality of Life. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900315.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine
  •  go-up   go-down


75. Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK, Locarnini S, Chan HL: Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol; 2008 Apr;82(7):3604-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.
  • We aimed to identify genomic markers in hepatitis B virus (HBV) that are associated with hepatocellular carcinoma (HCC) development by comparing the complete genomic sequences of HBVs among patients with HCC and those without.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. DNA, Viral / genetics. Genome, Viral. Hepatitis B virus / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Female. Genetic Markers. Genotype. Humans. Male. Middle Aged. Phylogeny. Point Mutation. Sequence Analysis, DNA. Sequence Homology. Viral Proteins / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Mar;118(3):554-9 [10702206.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):177-82 [18182659.001]
  • [Cites] J Med Virol. 2001 Jul;64(3):299-304 [11424118.001]
  • [Cites] J Med Virol. 2001 Oct;65(2):257-65 [11536231.001]
  • [Cites] J Viral Hepat. 2002 Mar;9(2):149-56 [11876799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6991-6 [12011457.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):175-81 [12210405.001]
  • [Cites] Hepatology. 2003 Jan;37(1):19-26 [12500184.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S491-6 [12534784.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):327-34 [12557138.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31745-55 [12799372.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5598-603 [14662947.001]
  • [Cites] Clin Infect Dis. 2004 May 1;38(9):1222-8 [15127332.001]
  • [Cites] Brief Bioinform. 2004 Jun;5(2):150-63 [15260895.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1593-8 [15090469.001]
  • [Cites] Gut. 2004 Oct;53(10):1494-8 [15361502.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):2023-32 [15180947.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 [15508104.001]
  • [Cites] J Mol Evol. 1980 Dec;16(2):111-20 [7463489.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Korean Med Sci. 1999 Aug;14(4):424-30 [10485623.001]
  • [Cites] Ann Hum Genet. 1956 May;20(4):309-11 [13314400.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):265-72 [15713961.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2022-32 [15897987.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):681-7 [16517839.001]
  • [Cites] Semin Liver Dis. 2006 May;26(2):153-61 [16673293.001]
  • [Cites] Hepatology. 2000 Mar;31(3):763-8 [10706570.001]
  • (PMID = 18216102.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Genetic Markers; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2268484
  •  go-up   go-down


76. Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, Fan D, Feitelson MA: Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology; 2006 Mar;43(3):415-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin.
  • Intrahepatic expression of hepatitis B x antigen (HBxAg) is associated with the development of hepatocellular carcinoma (HCC), perhaps through trans-activation of selected cellular genes.
  • Extensive costaining between HBxAg, URG11, and beta-catenin was observed in infected liver and HCC nodules, suggesting a close relationship in vivo.
  • URG11 stimulates the beta-catenin promoter and hepatocellular growth and survival.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496348.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104025; United States / NCI NIH HHS / CA / CA48656; United States / NCI NIH HHS / CA / CA104025-04; United States / NCI NIH HHS / CA / CA66971; United States / NCI NIH HHS / CA / R01 CA104025-04; United States / NCI NIH HHS / CA / R01 CA104025
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Antigens; 0 / Neoplasm Proteins; 0 / Trans-Activators; 0 / beta Catenin; 0 / hepatitis B virus X protein
  •  go-up   go-down


77. Kakeda S, Korogi Y, Hatakeyama Y, Ohnari N, Oda N, Nishino K, Miyamoto W: The usefulness of three-dimensional angiography with a flat panel detector of direct conversion type in a transcatheter arterial chemoembolization procedure for hepatocellular carcinoma: initial experience. Cardiovasc Intervent Radiol; 2008 Mar-Apr;31(2):281-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of three-dimensional angiography with a flat panel detector of direct conversion type in a transcatheter arterial chemoembolization procedure for hepatocellular carcinoma: initial experience.
  • The purpose of this study was to assess the usefulness of a three-dimensional (3D) angiography system using a flat panel detector of direct conversion type in treatments with subsegmental transcatheter arterial chemoembolization (TACE) for hepatocellular carcinomas (HCCs).
  • [MeSH-major] Angiography / methods. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Imaging, Three-Dimensional. Liver Neoplasms / radiography. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography, Digital Subtraction. Artifacts. Child. Contrast Media. Female. Humans. Male. Middle Aged. Prospective Studies. Radiographic Image Enhancement / instrumentation. Radiographic Image Interpretation, Computer-Assisted. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026792.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


78. Pietrosi G, Miraglia R, Luca A, Vizzini GB, Fili' D, Riccardo V, D'Antoni A, Petridis I, Maruzzelli L, Biondo D, Gridelli B: Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol; 2009 Jul;20(7):896-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
  • PURPOSE: To assess the safety of transarterial treatments of hepatocellular carcinoma (HCC), and the statistical correlation of various patient factors with the frequency of complications, in selected patients with cirrhosis when adhering to well-standardized protocols.
  • Major complications included acute liver failure (n = 1, 0.1%), variceal bleeding (n = 2, 0.3%), moderate-to-severe ascites (n = 4, 0.6%), sepsis (n = 3, 0.4%), cholecystitis (n = 1, 0.1%), and diverticulitis (n = 1, 0.1%).
  • Constitutional syndrome (P = .0001), Child-Pugh score (P = .0001), ascites (P = .037), and the Model for End-Stage Liver Disease score (P = .02) were found to have a statistically significant correlation with complications after univariate analysis.
  • CONCLUSIONS: Transarterial treatments can be considered safe in patients with Child class A and B cirrhosis when an adjusted dose of epirubicin is used according to body surface, severity of liver disease, and white blood cell count.
  • Accurate patient selection and procedure-related factors may reduce the frequency of complications and help preserve liver function.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / mortality. Epirubicin / administration & dosage. Fibrosis / mortality. Fibrosis / therapy. Liver Neoplasms / mortality. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Comorbidity. Dose-Response Relationship, Drug. Female. Humans. Italy / epidemiology. Male. Middle Aged. Prevalence. Risk Assessment. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497762.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


79. Wilson SR, Burns PN: An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol; 2006 May;186(5):1401-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography.
  • OBJECTIVE: The objective of this study was to develop an algorithm for liver mass diagnosis using microbubble contrast-enhanced pulse-inversion sonography.
  • SUBJECTS AND METHODS: Ninety-six lesions in 92 patients were evaluated with DMP 115 (Definity)-enhanced pulse-inversion sonography, comprising 44 malignancies (29 hepatocellular carcinomas, 12 metastases, two peripheral cholangiocarcinomas, and one hepatic lymphoma) and 52 benign lesions (26 hemangiomas, 20 focal nodular hyperplasias, and six others).
  • Combinations of answers were compared with independently determined final diagnoses to develop an algorithm for liver mass diagnosis.
  • Sustained portal phase enhancement with arterial phase peripheral nodularity and centripetal progression predicted 24 (92%) of 26 of the hemangiomas; diffuse arterial phase enhancement greater than the liver identified 19 (95%) of 20 of the focal nodular hyperplasias.
  • With negative portal phase enhancement, arterial phase information was less effective at differentiating hepatocellular carcinoma (25 [86%] of 29 cases) from another hepatic malignancy (11 [73%] of 15 cases).
  • CONCLUSION: A simple diagnostic algorithm for interpretation of microbubble-enhanced sonography provides sensitive and accurate diagnosis of commonly encountered liver masses.
  • [MeSH-major] Algorithms. Contrast Media. Liver Neoplasms / ultrasonography. Microbubbles
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632737.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


80. Jan CF, Chen CJ, Chen HH: Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol; 2005 Apr;20(4):521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience.
  • BACKGROUND: Since 1991, a rapid rise in mortality from hepatocellular carcinoma (HCC) has been observed in Taiwan in subjects aged >/=20 years.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Incidence. Male. Middle Aged. Poisson Distribution. Risk Factors. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 15836699.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


81. Fani A, Fani I, Eshratie B, Samadian P, Fani P, Gorishi Y: Screening for hepatocellular carcinoma in hepatitis B and C chronic carriers in Iran. Indian J Gastroenterol; 2007 Nov-Dec;26(6):297-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for hepatocellular carcinoma in hepatitis B and C chronic carriers in Iran.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / virology. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Liver Neoplasms / epidemiology. Liver Neoplasms / virology
  • [MeSH-minor] Adult. Carrier State. Cross-Sectional Studies. Female. Humans. Iran / epidemiology. Male. Middle Aged. Prevalence

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431018.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] India
  •  go-up   go-down


82. Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, Pinzani M: Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol; 2009 Apr-Jun;8(2):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease.
  • Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide.
  • The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma.
  • In this context, it is particularly important to identify patients at risk for progressive chronic liver disease.
  • Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis.
  • [MeSH-major] Fatty Liver / diagnosis. Liver Cirrhosis / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biomarkers / analysis. Biopsy. Child. Elasticity Imaging Techniques. Humans. Predictive Value of Tests. Reproducibility of Results. Risk Assessment. Risk Factors. Severity of Illness Index


83. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C, HENCORE Group: Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat; 2007 Aug;14(8):556-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.
  • The occurrence of decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation was analysed in relation to different host and viral factors.
  • Among patients who were sustained responders at inclusion, 2.3% developed liver complications during follow up, and 31% of non-responders did.
  • Long-term follow up of HCV patients indicates that virological response persists over time and is associated with a very low incidence of liver complications.
  • Advanced age at inclusion, advanced age at infection, viral genotype 1, non-response to previous therapy and possibly some specific HLA alleles are factors independently associated with a faster rate of progression towards liver complications.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepacivirus / growth & development. Hepatitis C / complications. Liver Cirrhosis / virology. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Disease Progression. Female. Follow-Up Studies. Histocytochemistry. Humans. Male. Middle Aged


84. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, White RI Jr, Nishimura T: Value of Micronester coils in port-catheter implantation for continuous hepatic arterial infusion chemotherapy with fixed catheter tip method. Eur Radiol; 2008 Jan;18(1):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cohort of this study was 143 consecutive patients with unresectable advanced liver cancer for whom a port-catheter system was percutaneously implanted.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Catheters, Indwelling. Embolization, Therapeutic / instrumentation. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography, Digital Subtraction. Chi-Square Distribution. Contrast Media. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2002 Feb;12(2):443-9 [11870447.001]
  • [Cites] Radiology. 2004 Mar;230(3):792-802 [14739309.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1611-7 [12438064.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14 (5B):2215-9 [7840526.001]
  • [Cites] Clin Radiol. 1999 Apr;54(4):221-7 [10210340.001]
  • [Cites] Radiology. 2000 Apr;215(1):294-9 [10751501.001]
  • [Cites] AJR Am J Roentgenol. 1977 Nov;129(5):799-803 [143878.001]
  • [Cites] Cancer. 1979 Aug;44(2):414-23 [157798.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1332-9 [15788620.001]
  • [Cites] Angiology. 1990 Nov;41(11):936-41 [2244698.001]
  • [Cites] Cardiovasc Intervent Radiol. 1997 Mar-Apr;20(2):128-32 [9030504.001]
  • [Cites] J Vasc Interv Radiol. 2003 Jan;14(1):63-8 [12525587.001]
  • [Cites] Radiology. 1997 Feb;202(2):574-7 [9015093.001]
  • [Cites] Semin Oncol. 1983 Jun;10 (2):135-47 [6306833.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1112-8 [1296590.001]
  • [Cites] Lancet. 1994 Nov 5;344(8932):1255-60 [7526096.001]
  • [Cites] J Vasc Interv Radiol. 2001 Oct;12(10):1215-8 [11585889.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 Nov-Dec;26(6):554-6 [15061181.001]
  • (PMID = 17619883.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


85. Xu L, Qian G, Tang L, Su J, Wang JS: Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol; 2010 Oct;53(4):671-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China.
  • BACKGROUND & AIMS: Southern Guangxi area is one of the endemic areas for hepatocellular carcinoma (HCC) in China.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20650537.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090997; United States / PHS HHS / / R01 90997
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9N2N2Y55MH / Aflatoxin B1; K3Z4F929H6 / Lysine
  •  go-up   go-down


86. Chong WP, To YF, Ip WK, Yuen MF, Poon TP, Wong WH, Lai CL, Lau YL: Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology; 2005 Nov;42(5):1037-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recruited 320 nonprogressed hepatitis B surface antigen (HBsAg) carriers; 199 progressed HBsAg carriers with hepatocellular carcinoma or cirrhosis; 87 spontaneously recovered individuals who were HBsAg negative and anti-HBs and anti HBc positive; and 484 controls who were naïve to HBV.
  • However, the low MBL genotypes had a dose-dependent correlation with the cirrhosis and hepatocellular carcinoma in progressed carriers with odds ratios of 1.36 and 3.21 for the low and extremely low MBL genotypes, respectively (P = .01).
  • The low-expression promoter haplotype XA (OR = 1.97) and the mutant haplotype YB (OR = 1.90) were also associated with the cirrhosis and hepatocellular carcinoma (P = .002).
  • In conclusion, these results suggest that low MBL genotypes associate with the occurrence of cirrhosis and hepatocellular carcinoma in progressed HBsAg carriers, and MBL can bind HBsAg.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Codon. Complement C4 / metabolism. Disease Progression. Female. Genotype. Hepatitis B Surface Antigens / blood. Hepatitis B Surface Antigens / metabolism. Humans. Liver Cirrhosis / genetics. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hepatology. 2006 Jan;43(1):199
  • (PMID = 16231358.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Complement C4; 0 / Hepatitis B Surface Antigens; 0 / MBL2 protein, human; 0 / Mannose-Binding Lectin
  •  go-up   go-down


87. Moriyama M, Arakawa Y: Treatment of interferon-alpha for chronic hepatitis C. Expert Opin Pharmacother; 2006 Jun;7(9):1163-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with chronic hepatitis C, IFN-alpha monotherapy results in a significant increase in the cumulative survival rate by suppressing the progression to hepatocellular carcinoma or liver failure.
  • In addition, other efficacious therapeutic regimens have been employed, such as prolonged administration of standard IFN-alpha in elderly patients; prolonged low-dose continuous administration in patients with decompensated cirrhosis or hepatocellular carcinoma postoperative patients; and combination therapy with 5-fluorouracil and standard IFN-alpha for advanced hepatocellular carcinoma.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / prevention & control. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Cirrhosis / drug therapy. Liver Failure / prevention & control. Liver Neoplasms / prevention & control
  • [MeSH-minor] Adult. Clinical Trials as Topic. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / therapeutic use. Recombinant Proteins. Ribavirin / administration & dosage. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732703.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 84
  •  go-up   go-down


88. Vashakidze E, Kiladze L, Gegeshidze T: Hemopoetic organs damage syndrome in patients with chronic viral hepatitis. Georgian Med News; 2005 Feb;(119):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver cirrhosis and hepatocellular carcinoma are the most frequent and severe complications of chronic hepatitis C.
  • Our investigation suggests that there is no absolute correlation between chronic hepatitis C activity and hematological disorders and often the degree of extrahepatocellular disorders is higher than the degree of liver damage.
  • [MeSH-minor] Adolescent. Adult. Aged. Enzyme-Linked Immunosorbent Assay. Erythrocytes / physiology. Female. Hematologic Tests. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Platelet Adhesiveness. Platelet Aggregation. Platelet Count. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834181.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


89. Heilmaier C, Lutz AM, Bolog N, Weishaupt D, Seifert B, Willmann JK: Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging. Radiology; 2009 Dec;253(3):724-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging.
  • PURPOSE: To retrospectively compare, in a multiobserver study, double-contrast-material (sequential administration of ferucarbotran and gadobutrol) magnetic resonance (MR) imaging with single-contrast-material ferucarbotran-enhanced and dynamic postferucarbotran gadobutrol-enhanced MR imaging for the detection and characterization of benign and malignant focal liver lesions.
  • Eighty-nine patients with a total of 128 focal liver lesions underwent double-contrast liver MR imaging (nonenhanced, ferucarbotran-enhanced, and dynamic postferucarbotran gadobutrol-enhanced MR imaging performed during one session).
  • Four readers independently reviewed the data sets during three reading sessions focused on focal liver lesion detection and characterization: In session 1, the nonenhanced and dynamic postferucarbotran gadobutrol-enhanced images obtained at double-contrast MR imaging were analyzed.
  • The benign and malignant focal liver lesions were differentiated with significantly higher confidence (P < or = .01) on the double-contrast (area under ROC curve [A(z)] = 0.988) and ferucarbotran-enhanced (A(z) = 0.985) MR images than on the dynamic gadobutrol-enhanced images (A(z) = 0.963).
  • Accuracy in the diagnosis of hepatocellular carcinoma (HCC) was highest (P = .02) and confidence in the final diagnosis of HCC (P = .001) or metastasis (P = .049) was significantly higher with double-contrast imaging.
  • CONCLUSION: In select cases, double-contrast MR imaging can improve diagnostic accuracy and increase confidence in characterizing focal liver lesions as HCC or metastasis.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Ferrosoferric Oxide. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Contrast Media / administration & dosage. Dextrans. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted. Magnetite Nanoparticles. Male. Middle Aged. ROC Curve. Retrospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ferumoxides .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789232.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Organometallic Compounds; 1BJ477IO2L / gadobutrol; G6N3J05W84 / ferumoxides; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


90. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL, Adefovir Dipivoxil 438 Study Group: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology; 2006 Dec;131(6):1743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Treatment with adefovir dipivoxil for up to 240 weeks was well tolerated and produced significant, increasing improvement in hepatic fibrosis, durable suppression of HBV replication, normalization of liver enzymes, and delayed development of resistance.
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Carcinoma, Hepatocellular / etiology. DNA, Viral / blood. Dose-Response Relationship, Drug. Double-Blind Method. Drug Administration Schedule. Female. Hepatitis B virus / genetics. Humans. Liver Cirrhosis. Liver Neoplasms / etiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087951.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 0 / Organophosphonates; EC 2.6.1.2 / Alanine Transaminase; JAC85A2161 / Adenine; U6Q8Z01514 / adefovir dipivoxil
  •  go-up   go-down


91. Verma V, Chakravarti A, Kar P: Cytokine levels of TGF-beta, IL-10, and sTNFalphaRII in type C chronic liver disease. Dig Dis Sci; 2008 Aug;53(8):2233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine levels of TGF-beta, IL-10, and sTNFalphaRII in type C chronic liver disease.
  • The aim of the study was to detect serum levels of TGF-beta, IL-10, and sTNFalphaRII in patients with type C chronic liver disease (CLD) and to correlate these with biochemical and histopathological parameters used to assess the severity of the disease.
  • It is inferred that cytokine levels reflect the level of inflammation in chronic hepatitis C virus (HCV) infection and can be used as indirect markers to assess the severity of liver disease.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Hepatitis C, Chronic / immunology. Interleukin-10 / blood. Liver Cirrhosis / immunology. Liver Neoplasms / immunology. Receptors, Tumor Necrosis Factor, Type II / blood. Transforming Growth Factor beta / blood
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Biomarkers / blood. Disease Progression. Female. Humans. Male. Middle Aged. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1999 Feb;30(2):185-91 [10068094.001]
  • [Cites] Clin Biochem. 2001 May;34(3):173-82 [11408014.001]
  • [Cites] Semin Liver Dis. 1995 Feb;15(1):70-81 [7597446.001]
  • [Cites] Bull Acad Natl Med. 2003;187(6):1147-60; discussion 1160-1 [14978874.001]
  • [Cites] Annu Rev Immunol. 2004;22:929-79 [15032600.001]
  • [Cites] J Biomed Sci. 2001 Jul-Aug;8(4):321-7 [11455194.001]
  • [Cites] J Clin Microbiol. 1996 Feb;34(2):417-23 [8789027.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Apr;18(4):393-403 [12653887.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):97-106 [16298544.001]
  • [Cites] Turk J Gastroenterol. 2003 Mar;14(1):7-11 [14593531.001]
  • [Cites] Cytokine. 2002 Jan 21;17 (2):108-17 [11886178.001]
  • [Cites] Clin Exp Immunol. 1997 Sep;109(3):458-63 [9328122.001]
  • [Cites] Hepatology. 2003 Apr;37(4):802-9 [12668973.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6624-30 [16425355.001]
  • [Cites] Clin Biochem. 2001 May;34(3):167-71 [11408013.001]
  • [Cites] Trop Gastroenterol. 2005 Oct-Dec;26(4):183-7 [16737047.001]
  • [Cites] Hepatology. 1996 Feb;23(2):210-7 [8591843.001]
  • (PMID = 18080762.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biomarkers; 0 / IL10 protein, human; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10
  •  go-up   go-down


92. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE: Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs; 2005 Oct;23(5):489-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Eligible patients had histologically-confirmed metastatic pancreatic adenocarcinoma or metastatic, locally advanced or recurrent cancer of the liver, bile duct or gallbladder, and had received no prior chemotherapy for advanced disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Oligopeptides / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Depsipeptides. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(6):507-15 [10321512.001]
  • [Cites] Mol Pharmacol. 2000 Jan;57(1):180-7 [10617693.001]
  • [Cites] Prostate. 1998 Feb 15;34(3):175-81 [9492845.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4205-8 [11106233.001]
  • [Cites] Biochem Pharmacol. 1990 Jun 15;39(12):1941-9 [2353935.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):95-8 [12694660.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):525-31 [10100703.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):299-306 [9488599.001]
  • [Cites] Invest New Drugs. 2001;19(4):335-40 [11561695.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1293-301 [10778954.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):227-8 [10761761.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(3):225-32 [8646796.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):451-3 [12393982.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]
  • (PMID = 16133801.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA63187
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / Oligopeptides; 110417-88-4 / dolastatin 10
  •  go-up   go-down


93. Momiyama K, Nagai H, Sumino Y: Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol; 2009 Jul;64(2):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
  • The aim of this study was to retrospectively assess changes of host immunity in relation to efficacy in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by combined intra-arterial chemotherapy.
  • METHODS: Thirty-seven adult Japanese LC patients with aHCC were treated by intra-arterial combination chemotherapy.
  • The control group was composed of 19 adult Japanese patients with chronic hepatitis C diagnosed by pathological examination of liver biopsy specimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / immunology. Liver Cirrhosis / immunology. Liver Neoplasms / immunology. Th2 Cells / immunology

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011857.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Bae JJ, Rho JW, Lee TJ, Yun SS, Kim HJ, Choi JH, Jeong D, Jang BC, Lee TY: Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep; 2007 Oct;18(4):1007-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients.
  • Loss of heterozygosity (LOH) in the 10q23 chromosomal region was analyzed in 18 tissue samples from Korean hepatocellular carcinoma (HCC) patients.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Chromosomes, Human, Pair 10 / genetics. Liver Neoplasms / genetics. Loss of Heterozygosity. Microfilament Proteins / genetics. Mutation
  • [MeSH-minor] Adult. Aged. Female. Gene Deletion. Genes, Tumor Suppressor. Humans. Korea / epidemiology. Male. Microsatellite Instability. Microsatellite Repeats. Middle Aged. PTEN Phosphohydrolase / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • Genetic Alliance. consumer health - Chromosome 10.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786367.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / tensins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


95. Hong CK, Yang JM, Kang BK, Kim JD, Kim YC, Chang UI, Yoo JY: A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis. Korean J Intern Med; 2007 Dec;22(4):283-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis.
  • Combined hepatocellular-cholangiocarcinoma is a rare form of primary liver cancer showing features of both hepatocellular and biliary epithelial differentiation.
  • We report here on a case with collision tumor, which apparently was the coincidental occurrence of both hepatocellular carcinoma and cholangiocarcinoma underlying schistosomiasis.
  • A 39-year-old-Philippine female was transferred to our hospital for evaluation of a liver mass that was found on ultrasonography at a local hospital.
  • Partial lobectomy was performed and we histologically identified the concurrent occurrence of hepatocellular carcinoma and cholangiocarcinoma, (a "collision type carcinoma").
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Schistosomiasis / physiopathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Female. Humans

  • Genetic Alliance. consumer health - Schistosomiasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):317-24 [10711445.001]
  • [Cites] Gut. 2000 Nov;47(5):721-7 [11034592.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2648-55 [11555575.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):235-44 [11580146.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1747-55 [6089997.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Am J Pathol. 1987 Jun;127(3):530-7 [2438941.001]
  • [Cites] Pathol Res Pract. 1987 Dec;182(6):783-91 [2449680.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):187-97 [2449824.001]
  • [Cites] J Pathol. 1988 Dec;156(4):305-10 [2465399.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Am J Clin Pathol. 1987 Feb;87(2):168-73 [3028121.001]
  • (PMID = 18309689.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687661
  •  go-up   go-down


96. Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM: Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol; 2009 Feb;20(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?
  • PURPOSE: To investigate risk factors and prognostic significance of postembolization fever (PEF)--a temperature of more than 38.0 degrees C--after chemoembolization in patients with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / mortality. Fever / mortality. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Risk Assessment / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy / statistics & numerical data. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084432.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Xu R, Bu-Ghanim M, Fiel MI, Schiano T, Cohen E, Thung SN: Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease. Semin Liver Dis; 2007 Feb;27(1):122-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatolenticular Degeneration / diagnosis. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Copper / analysis. Humans. Liver / chemistry. Liver / pathology. Liver Transplantation. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Wilson Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295181.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 789U1901C5 / Copper
  •  go-up   go-down


98. Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH: [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct;28(10):1810-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
  • OBJECTIVE: To evaluate the prophylactic efficacy of adefovir dipivoxil (ADV) for post-transplant recurrence of hepatitis B virus (HBV) with lamivudine-resistant YMDD mutation in liver recipients.
  • METHODS: From March 2004 to May 2006, 20 patients with chronic hepatitis B associated with YMDD mutant HBV prior to liver transplantation received treatment with ADV and additional intramuscular hepatitis B immunoglobulin (HBIG) for prevention of post-transplant graft reinfection.
  • The liver function, serum HBsAg, anti-HBs (HBIG), HBeAg, anti-HBc, anti-HBe, HBV DNA and creatinine were examined in all the patients before and after the transplantation.
  • Nineteen patients survived and one patient died of recurrent hepatocellular carcinoma.
  • CONCLUSION: ADV offers protection against recurrence of HBV with YMDD mutation after liver transplantation with only mild nephrotoxicity, but renal function monitoring during the use of ADV is still necessary.
  • [MeSH-major] Hepatitis B / prevention & control. Hepatitis B virus / genetics. Lamivudine / therapeutic use. Liver Cirrhosis / surgery. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Amino Acid Motifs. Antiviral Agents / therapeutic use. DNA-Directed DNA Polymerase / genetics. Drug Resistance, Viral. Female. Humans. Male. Middle Aged. Mutation. Recurrence

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971179.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 2T8Q726O95 / Lamivudine; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  •  go-up   go-down


99. Kang SG, Yoon CJ, Jeong SH, Kim JW, Lee SH, Lee KH, Kim YH: Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study. J Vasc Interv Radiol; 2009 Dec;20(12):1570-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study.
  • PURPOSE: To evaluate the efficacy and safety of a single-session combined chemoembolization and radiofrequency (RF) ablation for hepatocellular carcinomas (HCCs) less than or equal to 5 cm.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Chemoembolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Gelatin Sponge, Absorbable / administration & dosage. Humans. Iodized Oil / administration & dosage. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects. Radiography, Interventional. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19879777.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


100. He YF, Fan J, Zhou J, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, Yang GH, Song K, Wang Z, Tang ZY, Wang YQ: [Analysis of the risk factors influencing the prognosis of orthotopic liver transplantation for hepatocellular carcinoma and summary of relevant clinical experience]. Zhonghua Yi Xue Za Zhi; 2006 May 16;86(18):1232-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the risk factors influencing the prognosis of orthotopic liver transplantation for hepatocellular carcinoma and summary of relevant clinical experience].
  • OBJECTIVE: To analyze the risk factors influencing the prognosis of orthotopic liver transplantation for hepatocellular carcinoma (HCC) and sum up the relevant clinical experience in diagnosis and treatment of HCC.
  • CONCLUSION: Vascular invasion plays a leading role in evaluating the prognosis of orthotopic liver transplantation for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Vessels / pathology. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796877.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down






Advertisement